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vRÉSUMÉ
Les modèles de survie avec taux de guérison ont une vaste gamme d’applications dans de
nombreux domaines tels que la médecine et la santé publique, en particulier dans des études
sur le cancer. Dans ces études, les chercheurs sont intéressés par le temps d’attente jusqu’à
l’apparition d’un événement d’intérêt, ainsi qu’à la proportion des cas où cet événement ne
survient jamais, qualifiée dans ce contexte de taux de guérison. D’une manière générale, il
existe deux types de modèles pour l’estimation du taux de guérison. Le premier type est
le modèle de mélange avec taux de guérison. Ce type de modèles suppose que l’ensemble
de la population se compose de deux groupes d’individus : les individus susceptibles de
subir l’événement d’intérêt et les individus non susceptibles de subir l’événement d’intérêt,
ou immunisés. Le deuxième modèle est un modèle de non-mélange avec taux de guérison qui
se base, par exemple, sur le nombre de cellules cancéreuses qui restent après le traitement.
Ce mémoire conçoit et présente une revue des modèles de survie avec taux de guérison depuis
les premières études jusqu’aux articles récents. Puisqu’il n’y a pas d’étude exhaustive des
modèles de taux de guérison, ma mission se limitera au regroupement de tous les modèles
dans une notation unique et cohérente.
Les modèles de taux de guérison font partie de l’analyse de survie et incluent les cas de
censure. Par conséquent, pour une analyse convenable des modèles de taux de guérison, une
bonne connaissance de l’analyse de survie est nécessaire. Ainsi, au chapitre 2, les définitions
relatives aux sujets censurés et tronqués sont données. En outre, les concepts et formulations
de l’analyse de survie de base sont expliqués. Des modèles de survie courants, paramétriques,
non paramétriques et semi-paramétriques sont également expliqués. Les chapitres 3 et 4
forment la partie principale de ce mémoire ; ils portent essentiellement sur l’explication des
modèles de taux de guérison. Au chapitre 3, des tests préliminaires pour l’existence d’un taux
de guérison sont expliqués. Les premiers travaux dans les modèles de mélange avec taux de
guérison et certains modèles paramétriques et non paramétriques avec taux de guérison y
sont discutés. L’un des modèles de non-mélange avec taux de guérison et deux modèles de
mélange semi-paramétriques qui ont été adaptés des travaux plus récents dans les modèles
avec taux de guérison sont expliqués au chapitre 4.
Au chapitre 5, une étude de simulation a été effectuée pour chaque modèle introduit précédem-
ment afin d’en tester la précision. Les méthodes des études de simulation sont les mêmes que
celles utilisées dans les articles originaux. Au chapitre 6, les modèles avancés avec taux de
guérison sont mis en œuvre pour des bases de données de transplantation de moelle osseuse et
vi
les résultats sont discutés. Le chapitre 7 présente la conclusion de l’étude ainsi qu’un aperçu
d’une future recherche.
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ABSTRACT
Cure rate models have a broad range of application in many fields, such as medicine, public
health, and especially in cancer studies. Researchers in these studies are interested in waiting
time until occurrence of the event of interest, as well as the proportion of instances where
the event never occurs, known in this case as the cure fraction. In general, there are two
types of models for estimation of the cure fraction. The first one is the mixture cure rate
model. This type of models assumes that the whole population is composed of two groups
of subjects, susceptible subjects and insusceptible (or cured) subjects. The second model is
non-mixture cure model, based on number of cancer cells which remain after treatment. This
thesis devises and presents a review for cure rate models form early studies to recent articles.
Since there is not a comprehensive review on cure rate models, my mission was to put all
models together in a single and coherent notation.
Cure rate models are a part of survival analysis and involve censored subjects. Therefore,
analyses cure rate models a sufficient knowledge in survival analysis is required. In Chap-
ter 2, the definitions of censored and truncated subjects are given. In addition, the basic
concepts and formulations of survival analysis are explained. Some common parametric and
non-parametric, and semi-parametric survival models are explained as well.
Chapter 3 and Chapter 4 are the main body of this dissertation, and focus on explain-
ing cure rate models. In Chapter 3, some preliminary tests for existence of cured fraction
are described. Early works in mixture cure rate models and some parametric and non-
parametric cure models are discussed. In Chapter 4 non-mixture cure rate models and two
semi-parametric mixture cure rate models which are adopted from more recent works in cure
models are explained.
An extensive simulation study has been done for each model type and is discussed in Chapter
5. Simulation setup is the same as in original article and we were able to reproduce their re-
sults. In Chapter 6, advanced cure models are implemented for bone marrow transplantation
dataset. Chapter 7 presents the conclusion of the study and an overview of future research.
viii
TABLE OF CONTENTS
DEDICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
ACKNOWLEDGMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iv
RÉSUMÉ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
TABLE OF CONTENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
LISTE OF APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
CHAPTER 1 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
CHAPTER 2 SURVIVAL MODELS . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2 Censoring types and truncation . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.2.1 Right censoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2.2 Left censoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2.3 Interval censoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.2.4 Truncation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3 Analysis of survival data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.3.1 Likelihood construction . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.4 Survival models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.4.1 Nonparametric survival models . . . . . . . . . . . . . . . . . . . . . 11
2.4.2 Parametric survival models . . . . . . . . . . . . . . . . . . . . . . . . 12
2.4.3 Semiparametric survival models . . . . . . . . . . . . . . . . . . . . . 14
CHAPTER 3 CURE RATE MODELS: CLASSICAL APPROACH . . . . . . . . . . 18
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.2 Preliminaries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
3.2.1 Determination of cured fraction . . . . . . . . . . . . . . . . . . . . . 20
ix
3.2.2 Is the follow-up time long enough? . . . . . . . . . . . . . . . . . . . 21
3.3 Mixture cure rate models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.3.1 History . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.3.2 Formulation of mixture models . . . . . . . . . . . . . . . . . . . . . 24
3.3.3 Likelihood function for mixture models . . . . . . . . . . . . . . . . . 26
3.4 Parametric mixture models . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.4.1 Weibull and conditional logistic mixture model . . . . . . . . . . . . . 26
3.5 Nonparametric mixture models . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.5.1 Proportional hazard mixture model . . . . . . . . . . . . . . . . . . 28
CHAPTER 4 CURE RATE MODELS: MODERN APPROACH . . . . . . . . . . . 32
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
4.2 Semiparametric models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
4.2.1 Cure rate quantile regression mixture model . . . . . . . . . . . . . . 32
4.2.2 Two groups trial with semiparametric method . . . . . . . . . . . . . 37
4.3 Non-mixture models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
4.3.1 Semi-Parametric non-mixture models . . . . . . . . . . . . . . . . . . 42
CHAPTER 5 SIMULATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
5.1.1 Cure rate quantile regression model . . . . . . . . . . . . . . . . . . . 46
5.1.2 Two groups mixture model . . . . . . . . . . . . . . . . . . . . . . . . 48
5.2 Non-mixture models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
CHAPTER 6 APPLICATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
6.1 Data summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
6.2 Survival models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
6.2.1 Cox proportional hazard model . . . . . . . . . . . . . . . . . . . . . 52
6.3 Cure rate models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
6.3.1 Preliminary tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
6.3.2 Mixture models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
6.3.3 Non-mixture model . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
CHAPTER 7 CONCLUSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
7.1 Synthesis of cure rate models . . . . . . . . . . . . . . . . . . . . . . . . . . 60
7.2 Summary of simulation results and future work . . . . . . . . . . . . . . . . 61
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
xAPPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
xi
LIST OF TABLES
Table 2.1 Censoring schemes and the likelihood Function. . . . . . . . . . . . . 10
Table 5.1 Gamma estimation in cure rate quantile regression. . . . . . . . . . . 47
Table 5.2 Estimation of quantile coefficients in simulation study. . . . . . . . . 47
Table 5.4 Parameter estimation for non-mixture cure models. . . . . . . . . . . 49
Table 5.3 Parameter estimation for two groups mixture cure rate model. . . . . 50
Table 6.1 Cox proportional hazard model for bone marrow stransplant data. . . 55
Table 6.2 Cox proportional hazard cure rate model group ALL. . . . . . . . . . 56
Table 6.3 Cox proportional hazard cure model group AML high risk. . . . . . . 56
Table 6.4 Estimation of β0 in fitting cure rate quantile regression on BMT data. 57
Table 6.5 Estimation of β1 in fitting cure rate quantile regression on BMT data. 58
Table 6.6 Estimation of β2 in fitting cure rate quantile regression on BMT data. 58
Table 6.7 BMT data fitted by semiparametric two groups model. . . . . . . . . 58
Table 6.8 BMT data fitted by non-mixture model. . . . . . . . . . . . . . . . . 59
xii
LIST OF FIGURES
Figure 1.1 The concept diagram of cure rate models. . . . . . . . . . . . . . . . 3
Figure 2.1 Censoring and truncation illustration. . . . . . . . . . . . . . . . . . . 8
Figure 3.1 Kaplan-Meier estimator. . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 6.1 Kaplan-Meier estimate for each group of patients in BMT dataset. . . 53
Figure 6.2 Cumulative hazard estimate for each group of patients in BMT dataset. 54
xiii
LISTE OF APPENDICES
APPENDIX A R IMPLEMENTATION OF MIXTURE QUANTILE REGRESSION. 65
APPENDIX B R IMPLEMENTATION OF TWO GROUPS MIXTURE MODEL. . 72
APPENDIX C R IMPLEMENTATION OF NON-MIXTURE MODEL. . . . . . . . 75
1CHAPTER 1 INTRODUCTION
In many scientific studies, researchers are interested in waiting time until occurrence of an
event of interest. For instance, in many clinical trials, the study involves following patients
for a period of time and monitoring patient’s survival to assess the efficacy of new treatment
regimes. The event of interest in such studies could be death, hearth attack, relapse from
remission, or adverse reaction. If the event of interest is the heart attack, the waiting time
would be the time (in years or months) until the heart attack occurs. In survival analysis,
such event times are often the outcome of interest. Another example is in reliability studies,
where, for example, the repair history of manufactured items might be examined. The ques-
tion of interest is how long it takes for a manufactured item to be returned by the customer
for repair. The outcome variable in such studies is the length of time that a manufactured
item functions properly.
When the outcome variable is the waiting time until occurrence of an event the data are
called time-to-event data. A particular feature of time-to-event data is censorship. Censor-
ing happens when information about the outcome variable is incomplete. Consider a clinical
trial where the event times of some patients are missing due to loss-to-follow-up. It is clear
that ignoring such incomplete data can lead to incorrect inference. This is an example of
right censoring, one of the most common type of censoring among various censoring mech-
anisms. Censoring is divided into different types, which are discussed in more details in
Chapter 2. Incomplete information is studied in the context of survival analysis. Survival
analysis focuses on analyzing time-to-event data and often includes censored observations.
In addition to covering censored individuals in survival models, the response variable is al-
ways a positive real number, convenient for time-to-event data. Unlike ordinary statistical
models, for example regression models, survival models have two components for response
variable: one is the time-to-event and another is an indicator for each individual, whether
or not that individual is censored. An essential assumption in survival data analysis is that
every individual in the study will eventually experience the event of interest if they are fol-
lowed long enough. However, the event of interest may not occur for some individuals, even
after a very long period of follow-up time. The question is, what should been done for these
cases?
2Consider the heart attack example, where some of the patients do not die or relapse by the
end of the study. Many people experience a heart attack, but recover from this attack and
have a normal life for a long while before dying due to other causes is matter of interest.
How can we describe this fraction of patients? There are many follow-up studies that include
such cases where the standard survival models cannot accurately describe the behaviour of
all individuals. This flaw in modelling data with survival methods leads us to look for other
models to fit on time-to-event data with long term survivors. The fraction of individuals who
do not meet the event of interest even after a long period of follow-up is called cured fraction.
In the heart attack example, cured fraction consists of those patients who survived by the end
of the study and did not show any further sign of heart conduction. In the manufacturing
example, those items that did not fail nor malfunction during the examination comprise the
cured fraction. Thus, cured fraction is used to refer to any fraction of individuals who never
meet the event of interest, regardless of the nature of the study.
Since in real experiments there is always time restriction to follow-up the individuals, usu-
ally cured fraction appears in the dataset with censorship at the end point of the study
period. Cure rate models focus on modelling cured proportion who survived long enough
to be considered as the cured individuals. Additionally, cure rate models concentrate on
the probability of survival up to a certain time for those individuals who are not assumed
as cured. To model cured fraction we need to modify or extend existing survival models
in which those could include another set of parameters to explain nonzero limiting survival
probability. Most of the present cure models are modified survival models that include the
probability of being cured. There is the possibility of inferring the effect of covariates on
cured fraction by assuming a link function to connect the covariates to the probability of
being cured. Further discussion about this link function will be given in Chapter 3.
Although cure rate models have a shorter history compared to survival models, they have
been an area of active research in statistics since the early 50’s. Cure rate models can be
divided into two main categories, mixture cure rate models and nonmixture cure rate models.
The most widely-used cure rate model is the mixture cure model which is also known as the
standard cure rate model. This model was first introduced by Boag (1949). He introduced
the traditional definition of cured fraction for the patients who have a specific illness, by
five-years survival rate. Although the definition of cured fraction has changed and improved
over the years, many authors developed and improved the original mixture model further.
Berkson and Gage (1952) divided the population into two groups: susceptible individuals to
the event of interest and insusceptible individuals. They suggested that a group of treated
3Figure 1.1 The concept diagram of cure rate models.
patients is considered to be cured if they have approximately the same survival distribu-
tion as the general population who have never had the disease of interest. Farewell (1982)
used mixture model as a combination of logistic model and Weibull distribution to model
the toxicant and stress level for laboratory animals. KUK and CHEN (1992) proposed a
semi-parametric mixture cure model consisting of the logistic model for the probability of
occurrence of the event of interest, and the proportional hazard model to predict time-to-
event of interest. Maller and Zhou (1996) have collected a comprehensive account of mix-
ture cure rate models with various survival functions. Goldman (1984), Taylor (1995), and
Peng and Dear (2000), among others, have also investigated parametric, semi-parametric,
and non-parametric mixture cure rate models. More recently, Wu and Yin (2013) suggested
quantile regression methods and martingale estimation equation for a better assessment of
covariate effects on quantiles of event of interest.
The non-mixture cure model is another method for modelling time-to-event data with a
cure fraction. Non-mixture cure rate models were first introduced by Yakovlev et al. (1993)
and then discussed by Ming-Hui Chen (1999), Ibrahim et al. (2001), Chen et al. (2002), and
Tsodikov et al. (2003). These models were based on the underlying biological mechanism
and the assumption that the number of cancer cells that remain active and may grow after
cancer treatment follows a Poisson distribution. Most of the current investigations on the
non-mixture cure models are in the Bayesian context due to its special form. Moreover, these
two modelling methods, mixture and non-mixture cure rate models, are related, and have
meaningful connection together. The non-mixture cure rate models can be transformed into
4the mixture cure rate models, if the cured fraction is determined. In the future chapters we
will discuss these two models comprehensively.
We present some recent studies to demonstrate the progress in this area over the past decades.
The layout of this dissertation is as follow, see Figure 1.1. Chapter 2 introduces basic concepts
and primary definitions in survival analysis. In Chapter 3, we introduce statistical inferences
to test the presence of cured fraction in a sample of censored time-to-event data. We also
explain some selected early cure rate models from mixture. In Chapter 4 three of the more
recent mixture and non-mixture cure rate models are discussed. In Chapter 5 we carry
out several simulation studies for the models introduced in Chapter 4. In Chapter 6 we
apply all three different approaches to a real dataset. The chosen dataset is bone marrow
transplant dataset used to illustrate survival analysis methods in Klein and Moeschberger
(1997). Further discussion about the dataset is given in Chapter 6. In chapter 7 a conclusion
of the study and an overview of future research have been presented.
5CHAPTER 2 SURVIVAL MODELS
2.1 Introduction
Application of survival analysis abounds in medical and biological studies, among others.
In a considerably large portion of studies conducted in such areas, the outcome of interest
is time to an event. These types of dataset arise when some subjects are followed during
the study period under controlled conditions, to see whether the specific event of interest
happens or not. This event could be death or recurrence of a tumor, or discharge from a
hospital, or cessation of breastfeeding. This is why survival data are also being referred to
as time-to-event, or failure time data.
Survival, failure time or time-to-event data comprise an initiating event, say event of a dis-
ease, followed by a terminating event, say death. In most studies where the aim is to collect
such data, there are missing or partial information about either the initiating or the termi-
nating event or both. In retrospective studies, for instance, ascertainment of the initiating
event may not be possible with the desired accuracy. In prospective studies, the terminating
event may not be observed for some subjects. In cross-sectional sampling with follow-up
studies both cases can happen. In this later type of studies a further complication known as
biased sampling where the collected data do not form a representative sample from the target
population, may also happen. Such complications fall into two general categories: censoring
and truncation. Censoring is generally reserved for situation where only partial information
on some subjects under study is available, while truncation refers to cases where some sub-
jects in the population have no chance to be recruited to the study. There are different types
of censoring and truncation for survival data. We explain different types of censoring and
truncation with more details in the next section.
2.2 Censoring types and truncation
Censoring and truncation are two common features of time to event data. There are vari-
ous categories of censoring and truncation like right censoring, left censoring, and interval
censoring. The same versions exist for truncation, i.e. right truncation, left truncation and
interval truncation. Each category leads to a different likelihood function which will be the
basis for making statistical inference.
62.2.1 Right censoring
Right censoring, in general, means that the actual event time happens after the observation
is seized on a subject. Right censoring is perhaps the most common type of censoring and
has been extensively studied in the literature. There are several types of right censoring.
Below we describe the most common types of right censoring.
Type I right censoring: This type of censoring happens when the event occurs after some
prespecified time. In other words, there is a fixed follow-up time on each subject. In this
case, the study begins at a specific time and ends after passing a predetermined period of
time. The individuals could enter into the study once at the beginning of the study or they
could enter one by one with a random distance from the start point of the study. In the
later case, we can shift each individual’s starting time to 0, in order to have a convenient
representation for data. Those individuals who experience the event of interest before the
end of the study period are uncensored, others are considered to be censored. A typical
animal study or clinical trials are examples of this kind of data.
Type II right censoring: The type II right censoring happens when the starting time
of the study is predetermined but the ending time depends on the time when the first r
individuals, where r is some prespecified integer, experience the event of interest. Obviously
r should be an integer less than or equal to the total number of individuals recruited for the
study. An example of this kind of censoring can be seen in testing of equipment life; where
produced items are put on test at the same time, and the test is terminated when r of the
items fail.
Random right censoring: This type of censoring occurs when there are some other factors
except the event of interest which could remove some of the individuals from a trial during
the study period. Those factors are named competing events, and the individuals who have
been removed from the study are considered to be random right censored. In this case,
the event time and censoring time are often assumed to be independent of each other. In
many studies, the censoring scheme is a combination of type I censoring and random right
censoring.
72.2.2 Left censoring
Left censoring occurs when the event of interest happens some time before the beginning of
the study, the failure times are left censored.
An example of this kind of censoring is when we collect data by distributing a questionnaire
among students in a college to ask them about their first time they used marijuana if they
have used any. In this case, one of the answers could be that “ I used it but I do not know
when was the first time. ” This answer is an example of having left censoring. This type of
censoring commonly happens in retrospective studies.
2.2.3 Interval censoring
A more general kind of censoring happens when the event time is only known to have oc-
curred within an interval. Interval censoring happens when the individuals, involved in a
study, have a periodic follow-up.
2.2.4 Truncation
The difference between truncation and censoring is that we could have some censored indi-
viduals with partial information about their event time, while truncation is a feature that
limits our observation to only a part of the target population; subjects whose event time
meet some criteria. The criteria can be, for example, surviving beyond some age.
Like censoring, we have random and fixed left or right truncation, and interval truncation.
Fixed left (right) truncation occurs when only subjects whose event time is greater (smaller)
than a fixed age can be observed. In random left (right) truncation, the fixed age is replaced
by another positive random variable. For interval truncation, the event of interest should
happen within some prespecified interval for a subject to be observable. It is then clear that
fixed left and right truncations are special cases of interval truncation, where one side of the
interval is ∞ or −∞, for left and right truncation respectively. Figure 2.1 illustrates some
types of censoring and truncation.
2.3 Analysis of survival data
In this section we introduce some basic concepts in survival analysis.
Let T be the time to some specific event. We treat T as a random variable taking non-
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Figure 2.1 Dashed line for each individual is the time the individual is not observed. Straight
lines are the time that each individual is observed. Empty circles are the censoring time,
and solid circles are the time that event of interest happened. I1 is a complete observation,
I2 is random right censoring, and I3 is type I right censored individuals. I4 is random left
truncation, and I5 is an individual who are not observed because of truncation.
negative values. In survival analysis, instead of the cumulative distribution function of T ,
i.e. F (t) = P (T ≤ t), we mostly use survival function, which is the probability of an indi-
vidual surviving beyond time t. Survival function is denoted by S(t) = P (T > t). Another
fundamental concept in survival analysis is the hazard rate function (or risk function). This
function represents the instantaneous density of failure, i.e. the chance for an individual who
has survived until time t, to experience the event of interest in the next instant in time.
Mathematically the hazard rate function is defined by
h(t) = lim
∆t→0
P (t ≤ T < t+∆t|T ≥ t)
∆t
.
There is, of course, one-to-one correspondence between F , S(t) = (1−F (t)) and h(t). Below
we present these relationships.
S(t) = P (T ≥ t) =
∫ ∞
t
f(s)ds (2.1)
9F (t) = 1− S(t) (2.2)
f(t) = −
dS(t)
dt
(2.3)
h(t) =
f(t)
S(t)
=
−d log{S(t)}
dt
(2.4)
All the above formulas can be proved easily. You can refer to Klein and Moeschberger (1997).
In addition to all these definitions, another quantity is the cumulative hazard function H(t),
defined by:
H(t) =
∫ t
0
h(x)dx = − ln{S(t)}. (2.5)
Thus, we can have the following formula for continuous lifetime variable:
S(t) = exp{−H(t)} = exp{−
∫ t
0
h(x)dx} (2.6)
One aim of survival analysis is to fit a model, for any of the above three functions, on a
dataset. There are several ways to fit a model to data. Constructing the likelihood function
is one of the useful methods which helps us to fit parametric or non-parametric models on a
dataset. In the next section we illustrate how to construct the likelihood function for survival
datasets.
2.3.1 Likelihood construction
While constructing the likelihood function, it is necessary to take in to account censored and
truncated individuals. Whether an observation is censored, truncated, or an exact lifetime,
it will have a different effect on the likelihood estimation.
When the event has happened for an individual, the probability of occurrence of the event
at the time of happening is taken into account. Therefore, the probability density function
at the time of occurrence of the event of interest is integrated into the likelihood function.
When a right-censored observation exists, the probability of the individual survived past
the censoring time is taken into account in the likelihood function. This probability can be
approximated by the survival function evaluated at the censoring time. When a left-censored
observation occurs, it means the event has already taken place, and corresponding cumulative
density function evaluated at the censoring time contributes in the likelihood function. For
an interval-censored observation, it is known that event occurred inside an interval, and
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hence the probability of the event occurred during this interval (this can be calculated by
using either S(t) or F (t)) is added to the likelihood function. Confront with truncated
data means we should use a conditional probability function, because observed individuals
are those individuals who experience the event of interest within a certain time interval. For
example, having right-truncated data means the information, required for likelihood function,
is provided by chance of experiencing the event of interest at certain time conditional on not
surviving before the end of follow-up.
The likelihood function, L(θ), for a data set is constructed by taking the product of each
individual component. For example, consider a dataset that consists of the observed lifetimes
and right-censored observations. The likelihood for this data set in the case of independent
censoring and truncations is:
L(θ) ∝
∏
i∈D
fθ(xi)
∏
i∈R
Sθ(xi), (2.7)
where D and R represent the set of observed lifetimes and right-censoring times respectively,
and xi is the observed lifetime for ith individual, and θ is the statistical parameters.
The following table shows the information components that we can use for every censoring
scheme to construct likelihood function, see Klein and Moeschberger (1997).
Table 2.1 Censoring schemes and the Likelihood Function. Yl and Yr are the left and right
boundaries of follow-up time for truncated data. Cr and Cl are right and left censoring times
for censored individuals.
Likelihood Contribution Censoring Scheme
f(t) Observed lifetime
S(Cr) Right-censoring
1− S(Cl) Left-censoring
S(Cr)− S(Cl) Interval-censoring
f(t)/[1− S(Yr)] Right-truncation
f(t)/S(Yl) Left-truncation
f(t)
[S(Yl)−S(Yr)]
Interval-truncation
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2.4 Survival models
Analysing survival data requires to estimate the basic functions related to the data, like
survival function or hazard rate function. This estimation is possible through parametric,
nonparametric or semiparametric methods. Here, we introduce these methods briefly.
Different types of censoring lead to the different likelihood function. To avoid complexity
and redundant discussion, the concept of censored observation is limited to the right cen-
sored observations in this study. The other types of censoring have equivalent models and
inferences. During the current study, it has been considered that dataset includes typical
right censored individuals who are identified by the pair (xi, δi), in which xi is the observed
time, and δi is a Bernoulli indicator with value 1 for uncensored individuals and value 0 for
censored individuals.
2.4.1 Nonparametric survival models
To draw an inference about the distribution of some time to event variable, based on a sample
of right-censored dataset, Kaplan and Meier estimator (KME) is a replacement for empir-
ical distribution function for ordinary data. KME is a nonparametric estimation method;
Klein and Moeschberger (1997).
Kaplan-Meier estimator
Suppose Yi provides the number of individuals who are at risk at time xi. In other words, Yi
is the number of individuals who are alive and have not yet been censored up to time xi or
have observed time equal to xi. Again, assume Ei is the number of individuals who experi-
ence the event of interest at time xi. Therefore, the conditional probability that an individual
who survives just prior to time xi experiences the event of interest at time xi is equal to Ei/Yi.
The Product-Limit estimator proposed by Kaplan and Meier, in order to non-parametrically
estimate the proportion of the population whose lifetimes surpass time t, is defined by
Sˆ(t) =
∏
xi≤t
{1−
Ei
Yi
}. (2.8)
When t is less than the smallest observed survival time, then Sˆ(t) = 1. Unfortunately KME
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is not well defined when t is greater than the largest observed survival time.
The variance of KME is estimated by
Vˆ {Sˆ(t)} = Sˆ(t)2
∑
xi≤t
Ei
Yi(Yi − Ei)
. (2.9)
2.4.2 Parametric survival models
Parametric survival models have been used widely to analyze survival data. Parametric sur-
vival models fit a parametric survival function to a dataset. Then it is necessary to learn
more about the standard parametric survival functions, and other related functions that have
been introduced in Section 2.3.
In this section, we present briefly three parametric functions in survival analysis which have
frequently been used in analyzing such data. Exponential, Weibull, and lognormal are three
parametric functions we will discuss among all other models such as gamma, loglogistic, nor-
mal, exponential power law, and so on.
Exponential
This model suggests the density function for survival data with exponential distribution.
Using equations (2.1) to (2.6), we can easily obtain other related functions of exponential
survival model.
f(t) = λ exp(−λt), λ > 0, t ≥ 0 (2.10)
S(t) = exp(−λt), (2.11)
h(t) = λ. (2.12)
Because of the well-known feature of exponential distribution which is lack of memory or
memoryless property, we cannot fit this model for many real types of survival data. Because
this property provides E(T ) = 1/λ, that means, the mean residual life time is constant which
does not apply for many types of real data. We can see that exponential hazard function is
also constant, which adds another restriction in applying this model for real survival datasets.
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Weibull
Weibull distribution is being used commonly in survival analysis. With Weibull distribution,
we can bypass the restrictions of using exponential distribution, and have more freedom in fit-
ting different kinds of real datasets. The exponential distribution is a special case of Weibull
distribution. The related functions and parameters with this survival model are given below:
f(t) = αλtα−1 exp(−λtα), α, λ > 0, t ≥ 0 (2.13)
S(t) = exp(−λtα), (2.14)
h(t) = αλt(α−1), (2.15)
where α is the shape parameter and λ is the scale parameter. This model has more flexibility
to fit on real survival datasets. Because the hazard function of Weibull survival model can
take any form of increasing, decreasing or constant for different values of α, and λ.
Lognormal
A random variable T is said to follow the lognormal distribution if its logarithm (Y = ln T )
follows the normal distribution. This distribution has been widely used for time to event
datasets because of its relation to the normal distribution. We can specify this model by two
parameters, the location (µ), and the scale (σ) of Y . The following equations describe the
parameters of this model explicitly:
f(t) =
exp[−1/2{ ln(t)−µ
σ
}2]
t(2π)1/2σ
, σ > 0, t ≥ 0 (2.16)
S(t) = 1− Φ{
ln(t)− µ
σ
}, (2.17)
where Φ(x) is the cumulative distribution function of a standard normal variable. The hazard
ratio function can be obtained by the f(t)
S(t)
formula.
This survival model is very popular in applied survival analysis, because of its link to the
normal distribution function which is very powerful in modeling natural phenomenon.
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Accelerated failure time (AFT) model
So far, all the survival models that we have introduced are univariate survival models. But, In
many cases, we are interested in figuring out how some factors can affect the surviving time.
The factors are usually called covariates in the statistical literature. In other words, the event
time, T > 0 could be associated with a vector of explanatory covariates, z⊤ = (z1, z2, ..., zp).
The z⊤ may include quantitative or qualitative covariates or time-dependent covariates. In
this case, we are interested in ascertaining the relationship between time to failure variable T ,
and the covariates z⊤. This would be the case when we want to compare survival functions
for more than one treatment, or controlling of the confounders.
One approach to the modeling of covariate effects is to use classical linear regression. In this
approach, the natural logarithm of the time to event variable is denoted Y = ln(T ). This
transformation is used in order to convert positive variables to observations on the entire real
line. The linear model for Y is:
Y = β0 + z⊤β + ε, (2.18)
where β is a vector of regression coefficients, β0 is a constant, and ε is a random error.
Each error distribution yields a specific model for survival time. For example, if the error
distribution is the standard normal distribution, the survival time has lognormal regression
model. If the error distribution is the logistic distribution, survival time has the log-logistic
model, and the extreme value error distribution gives Weibull regression model. To know
more about error distributions, the reader can refer to Klein and Moeschberger (1997). This
method of modelling is called accelerated failure time model. We can find coefficients and
unknown parameters of the specific parametric model that we are using, by constructing and
maximizing a likelihood function.
2.4.3 Semiparametric survival models
Semiparametric models combine a parametric model for some components of the model and
keep nonparametric estimation for other components. The following sections describe some
of the semi-parametric methods in survival analysis.
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Modeling with hazard rate function
Although the modelling of the time to failure provides a very useful framework for a consider-
able number of cases in the real application, its use is restricted by the error distributions that
one considers. Conditional hazard rate as a function of the covariates is the major method
for modelling the effects of covariates on survival data. Two popular models are used for this
reason, one is the multiplicative hazard model, and the other one is the additive hazard rate
model. The following paragraphs describe these two approaches briefly.
Multiplicative hazard rate models: Consider for instance that we want to compare the
survival function of cancer patients on two different treatments. One form of a regression
model for the hazard function that could be used in such a model is:
h(t, z, β) = h0(t)r(z, β), (2.19)
in which the h0(t) could have any arbitrary parametric form or it can be any nonnegative
function of t, and r(z, β) is a nonnegative function of covariates which does not depend on
t. This model could contain both parametric and nonparametric factors. These factors must
be chosen so that h(t, z, β) > 0. The function h0(t) is called the baseline hazard function,
the hazard function for the subjects with covariates set to zero. It is equal to the hazard
function when r(z, β) = 1. The ratio of model (2.19), for two individuals with covariate
values denoted by z1, and z2, is:
HR(t, z1, z2) =
h(t, z1, β)
h(t, z2, β)
=
h0(t)r(z1, β)
h0(t)r(z2, β)
=
r(z1, β)
r(z2, β)
. (2.20)
It can be seen that the hazard ratio (HR) depends only on the function r(z, β). The impor-
tant part of estimation for this regression model is to determine a parametric form for r(z, β).
Cox (1972), one of the leaders in survival analysis, proposes the model (2.20). He suggested
the function ez
⊤β as a replacement for function r(z, β). In this case the hazard ratio (HR) is
equal to:
HR(t, z1, z2) = e(z1−z2)
⊤β. (2.21)
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If we use the equation (2.6), the survival function for this model has the following form:
S(t, z, β) = e−H(t,z,β). (2.22)
To obtain H(t, z, β), which is the cumulative hazard function at time t for a subject with co-
variate z, we can use the following method. Here, we assume the survival time is continuous.
For more information refer to Cox (1972).
H(t, z, β) =
∫ t
0
h(u, z, β)du = r(z, β)
∫ t
0
h0(u)du = r(z, β)H0(t), (2.23)
in which H0(t) is called the cumulative baseline risk. Thus it follows that
S(t, z, β) = [e−H0(t)]r(z,β) = {S0(t)}r(z,β), (2.24)
where, S0(t) = e−H0(t) is the base line survival function. So, under the Cox model the survival
function is equal to
S(t, z, β) = {S0(t)}exp(z
⊤β). (2.25)
Cox proportional hazard model (CPH) is useful when we want to compare two or more groups
of survival data, because by applying equation (2.20), there is no need to specify the base
line hazard function in the analysis of such datasets.
Additive hazard rate models: Consider we have an event time T whose distribution
depends on a vector of possibly time-dependent covariates, z⊤(t) = (z1(t), ..., zp(t)). We
assume that the hazard rate at time t, for each individual, is a linear combination of the
zk(t)′s:
h(t|z(t)) = β0(t) +
p∑
k=1
βk(t)zk(t), (2.26)
The p regression functions can be positive or negative, but the values are constrained because
h(t|z(t)) must be positive. Estimation for additive models is typically made by nonparamet-
ric (weighted) least-squares methods; see Klein and Moeschberger (1997) for more details.
Linear transformation models
A generalization of semi-parametric models proposed above is the linear transformation model
which has the form:
h(T ) = −z⊤β + ε, (2.27)
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where z is a vector of covariates and ε is a random error with distribution function F , and
β is a vector of coefficients. Another equivalent form of the linear transformation model is
defined by:
g{S(t|z)} = h(t) + z⊤β, (2.28)
in which h(t) is a completely unspecified strictly increasing function, and g(t) is a known
decreasing function such that g−1(t) = {1− F (t)}. By specifying the distribution of ε, F (t),
or specifying g(t) we can precisely determine the transformation model of equation (2.27). If
we consider F to be the extreme value distribution, F (x) = 1−exp{− exp(x)}, then equation
(2.27) has the form of proportional hazard model, since g(x) = log(− log(x)), and equation
(2.28) will convert to:
log[− log{S(t|z)}] = h(t) + z⊤β, (2.29)
which (this form) is equivalent to equation (2.25), the CPH model. The advantage of lin-
ear transformation model is its generality, since F could be any distribution function. The
reader can find the estimating equations of β in Cheng et al. (1995). The consistency and
asymptotic normality of the estimate of β has been proven in this article.
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CHAPTER 3 CURE RATE MODELS: CLASSICAL APPROACH
3.1 Introduction
Cure rate models are a special case of survival models where a portion of subjects in the
population never experience the event of interest. Such subjects are called immune or cured.
There are two platforms for cure models i) the mixture cure rate models, also known as
standard cure rate models, which have been widely used for modelling survival data with a
cured fraction. ii) the non-mixture cure rate models which have attracted less attention so
far.
The survival time of cured individuals might be censored at the end of the follow-up study.
Hence, if the follow-up time is long enough, there might be cured individuals in the dataset.
In general, however, cured individuals comprise a subset of censored individuals. The chal-
lenging aspect of fitting cure models on survival data is that the presence of cured fraction in
the sample is not obvious. It is recommended to test the existence of an immune fraction in
the sample before fitting cure models, and also test whether the follow-up is long enough or
not. In this chapter some preliminary tests are first introduced. We then present parametric
and non-parametric mixture cure models.
3.2 Preliminaries
One main reference for the materials in this section is Maller and Zhou (1996).
Farewell (1986) illustrates some restrictions that one confronts when applying cure models, in
particular, the mixture models. One restriction is that one needs strong scientific evidence for
the existence of two or more substructures in the population when applying mixture models
on a dataset. It is reasonable to think that cure models in a clinical setting are sensible
only if the data are based on a long-term follow-up study. The use of such models therefore
requires careful attention. Visually, the presence of cured fraction in the dataset can be seen
when the Kaplan-Meier survival curve reach a plateau, see in Figure 3.1. A test statistics to
verify the presence of a cured fraction is proposed below.
Let T with cumulative distribution function F , and C with cumulative distribution function
G, respectively, represent the failure and censoring time. Suppose δ is the censoring indicator,
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Figure 3.1 Kaplan-Meier estimator for group 1 of patients in bone marrow transplant data.
Doted lines are a confidence interval.
i.e. δ = 1 if T ≤ C, and 0 otherwise. Then the observations are D = {(xi, δi), i = 1, 2 . . . , n}
where xi = min(ti, ci), i = 1, 2, . . . , n and n is the sample size.
In general a cumulative distribution function A is a proper distribution function if
1. A(∞) = limt→∞A(t) = 1,
2. A(−∞) = 0.
The distribution function A(t) is improper if one of the above conditions does not apply. In
mixture cure rate formulations G(t), the distribution function of censoring times, is required
to be proper, but F (t), the distribution function of the event times, is not required to be a
proper cumulative distribution function; Maller and Zhou (1996, p. 31).
Suppose
p = P (T <∞) = F (∞) = lim
t→∞
F (t). (3.1)
The probability p is the proportion of individuals in the population who eventually experience
the failure, or the event of interest, if the follow-up time is long enough. This probability p
which is always less than or equal to 1, sometimes can be strictly less than 1. Therefore, the
immune fraction of population is 1− p, i.e. the proportion of individuals in the population
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who never experience the event of interest. From equation (3.1) it can be seen that F (t)
could be an improper distribution function.
Let
τA = inf{t ≥ 0 : A(t) = 1}; (3.2)
The τA is called the right extreme of the distribution A(t). If the function F (t) is an improper
distribution function τF is ∞, since F (t) ≤ F (∞) < 1, for all t.
In Section 3.2.1, we highlight some questions that should be addressed prior to analysing
time-to-event data.
3.2.1 Determination of cured fraction
Assume that τG < τF . This assumption is crucial for identifiability in nonparametric and
semi-parametric settings, but can be relaxed in parametric settings.
From equation (3.1) it is concluded that immune subjects are present in the population if
and only if
p = F (∞) < 1.
Since, if F (∞) = 1 there is no immune fraction. Given that it is impossible to calculate F (∞)
when F (t) is unknown, we consider F (τG) as the base for developing a test of hypothesis, as
it is suggested in Maller and Zhou (1996, p. 36).
We therefore consider H01 : F (τG) = 1 to test for the presence of immune fraction. If H01 is
accepted, there is no evidence of having an immune fraction. If H01 is rejected, we test for
having a long enough follow-up.
To obtain a value for τG, it is needed to know the distribution of the censoring time, G. In
most practical applications, however, G is unknown as well. Therefore, the largest observed
time in the sample is used instead of τG. Suppose x(n) is the largest observation, censored or
uncensored, in the sample, and Fˆn{x(n)} is the value of Kaplan-Meier estimator at x(n). A
nonparametric estimator of p is
pˆn = Fˆn{x(n)}. (3.3)
It has been proved that Fˆn{x(n)} is a consistent estimator for F (τG) under a mild continuity
condition and τG ≤ τF ; see Maller and Zhou (1996, chap. 3). Since Fˆn{x(n)} is an estimate
for F (τG), if pˆn = 1, H01 is accepted and there is no immune fraction in the population. To
summarize,
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Reject H01 if pˆn < cα, (3.4)
where cα is the αth percentile of the distribution of pˆn under H01. To obtain the value of cα, the
distribution of pˆn is needed, and in general this distribution is unknown; see Maller and Zhou
(1996) 1 who performed simulations to estimate the value of cα, when α is equal to 1%, 5%,
10%, or 20%.
3.2.2 Is the follow-up time long enough?
Observations in a sample may consist of two different groups, the cured individuals (we some-
times refer to them as insusceptible or immune individuals), and the uncured (we sometimes
refer to them as susceptible or nonimmune). Note that susceptible individuals could be either
censored or not censored, i.e. those individuals whose event time is observed during the study
period are not censored.
Suppose
F ∗(t) =
F (t)
F (∞)
.
The function F ∗(t) is the proper distribution function of susceptible individuals, i.e.
F ∗(∞) =
F (∞)
p
= 1.
Analogously, τF ∗ is the extreme value of the survival times of susceptible individuals.
When τF ≤ τG, we may observe the largest possible event time up to the maximum possible.
In contrast, when τF > τG, it means censoring is so heavy and we may not be able to observe
all event times.Therefore, τF ≤ τG can be used to examine whether the follow-up time is
enough. Note that for susceptible individuals if ti ≤ ci then the failure time for individual
ith is observed. It is straightforward that τF ∗ < τF . In Maller and Zhou (1996) τF ∗ ≤ τG is
considered as the reference for enough follow-up time. For more details see Maller and Zhou
(1996, p. 33).
1Maller and Zhou (1996), Appendix A.1 and A.2.
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Therefore the desired hypothesis test for sufficient follow-up time is


H02 : τF ∗ ≤ τG
Hc02 : τF ∗ > τG.
(3.5)
This means only the magnitude of τG − τF ∗ needs to be estimated, the distance between
largest possible censored time and largest possible failure time of susceptible individuals.
Assume x(n) is the largest observed survival time; and t(n) is the largest uncensored failure
time, it has been proved that
x(n) − t(n) →


τG − τF ∗ if τG ≤ τF ∗
0 if τG > τF ∗ ,
almost surely as n→∞ (Maller and Zhou (1996)).
Consequently, long enough follow-up time is the result of two conditions:
i) whether the presence of immune fraction is accepted in the sample, i.e. H01 is rejected.
ii) if x(n) − t(n) is large enough.
Then one can accept that the follow-up is sufficient. However, since the distribution of
x(n) − t(n) is unknown, a simpler quantity should be found to perform this hypothesis test.
To this end Maller and Zhou (1996) defined
qn =
Nn
n
=
Number of uncensored xi in the interval (2t(n) − x(n), t(n)]
Number of sample individuals
(3.6)
to test this hypothesis.
Large values of qn suggest rejecting Hc02 or equivalently accepting H02. This means the follow-
up time is long enough. However, how large qn must be to accept H02 is still unclear, since
the distribution of qn (and Nn) is unknown. Again the simulation results of Maller and Zhou
(1996) can be used to evaluate the percentiles of distribution of qn. If the value of qn ex-
ceeds the tabulated (1−α)th percentile (for α equal to 1%, 5%, 10%, or 20%), H02 is accepted.
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3.3 Mixture cure rate models
Most of the early works in cure rate models are based on parametric mixture models. In this
section we aim to explain one of the earliest work in mixture cure rate models. Some other
parametric, nonparametric, and semi-parametric methods are discussed in sections 3.4, 3.5,
and Chapter 4. We start with a simple parametric version of mixture cure rate model, using
the exponential distribution function for the survival time.
3.3.1 History
The paper by Berkson and Gage (1952) is our main reference in this section. The idea of
mixture cure rate models originates from comparison between survival curves of two groups
of subjects. One group is the patients under a specific treatment, and the other is a sample
from a control group. Consider logarithm of survival times in drawing two survival curves
and draw them on one figure. The ratio of survival times of two groups can be found by
vertical difference between the two curves. It has been shown that the two curves approxi-
mately become parallel after passing some time. It means the instantaneous failure rate for
the two curves is equal, and failure rate for group of patients who are under the treatment
becomes equal to failure rate for the controlled group, at some point. Cured fraction is the
proportion of patients who are subject to normal failure rate in the controlled group. This
definition of cured fraction first appeared in Berkson and Gage (1952).
Berkson and Gage (1952) divide the population in two hypothetical groups, one group is just
subject to normal failure rate which is called cured fraction. The other group is subject to
normal failure rate and a specific failure rate which could be the failure rate for a disease
under the study. These two failure rates are represented by q0, for normal failure rate, and
qca, for the specific failure rate of the disease. These two failure rates act independently and
simultaneously. Assume the two groups act separately, then the probability of survival for
the cured fraction is l0 =
∏n
i=1(1− q0), and the probability of survival for uncured fraction is
l0lca, in which lca =
∏n
i=1(1− qca).
Berkson and Gage (1952) made another assumption to simplify their modelling. They con-
sidered the rate of death caused by the specific disease to be a constant (say β), i.e. the
hazard function for uncured population is β. So the survival probability for the uncured
population should decrease exponentially and be time-varying, implying that lca(t) = e−βt.
By considering p as the cured fraction in our population, the probability of survival up to
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time t for total population is
Probability of survival up to time t = pl0 + (1− p)l0e−βt. (3.7)
The unknown parameters in equation (3.7) are p and β. Dividing both sides of equation (3.7)
by l0 we have
Probability of survival up to time t
l0
= p+ (1− p)e−βt. (3.8)
The equation (3.8) can be interpreted as the probability of survival in the whole population.
This interpretation is valid only if the population is free of death by any other causes, except
the disease of interest. Parameters p and β are estimated by least squares method using one
of the numerical minimization routines. For complete details of minimization methods see
Berkson and Gage (1952).
Berkson and Gage (1952) did not consider any censorship for the data during the experi-
ment. Cured individuals are those who survive by the end of the experiment, and uncured
individuals are those who are faced with the event of interest during the follow-up.
3.3.2 Formulation of mixture models
In survival analysis, observations usually consist of the following random variables.
Random variable X = min{T, C}, where T is the failure time, and C is censoring time, and
Bernoulli variable δ = 0 if the individual is censored, and is equal to 1 otherwise. Also, some
covariates may be added to these variables. We often assume that T and C are independent.
Subjects can be divided in another category which divides individuals between susceptible
(uncured) and insusceptible (cured) individuals. A Bernoulli random variable η is an indi-
cator for susceptibility of each individual. This variable η takes value 1 if the individual is
susceptible and 0 otherwise. Of course, η is not observed; essentially, there is no information
from a study, but it has been used as a latent variable in the model formulation. To distin-
guish properly the difference between variables η and δ, consider η as the true event status and
δ as the observed failure status; essentially, {δi = 1, i = 1, . . . , n} ⊂ {ηi = 1, i = 1, . . . , n},
where i denotes an individual and n is sample size. The latent variable η enable us to divide
event time in two categories: those individuals who meet the event, and those who never
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meet the event of interest. Following the decomposition for event (failure) time:
T = ηT ∗ + (1− η)∞. (3.9)
Equation (3.9) illustrates that failure time T is decomposed by T ∗, the survival time of
susceptible individuals, and survival time of insusceptible individuals which conventionally
is considered to be ∞ and never happens. By introducing η the true survival time, T = ∞
becomes reasonable. We introduced before F ∗(t) as the proper cumulative distribution for
survival time; thus,
P (T ≤ t|η = 1) = F ∗(t), (3.10)
P (T ≤ t|η = 0) = 0. (3.11)
The density and survival functions of cured individuals are set to zero and one, respectively,
for all finite values of t because cured (insusceptible) individuals will never experience the
failure. Thus,
F (t) = P (T ≤ t) = P (T ≤ t|η = 1)P (η = 1) + P (T ≤ t|η = 0)P (η = 0) (3.12)
= pF ∗(t) + 0 = pF ∗(t). (3.13)
The last equality holds since P{η = 1} = p. The overall formulation of a mixture cure rate
model is derived from the above equation. Briefly, the mixture cure rate models have the
form
F (t) = pF ∗(t), (3.14)
or equivalently,
S(t) = (1− p) + pS∗(t). (3.15)
The functions S(t) and S∗(t) are improper and proper cumulative survival functions of T .
Consequently, f ∗(t) is a proper density function of T .
In the previous part, equation (3.7) is equivalent to the mixture formulation of equation
(3.15), if T has exponential distribution with parameter β.
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3.3.3 Likelihood function for mixture models
The general likelihood function for mixture rate cure model is
L(θ, p) =
n∏
i=1
{pf ∗θ (t)}
δi{pS∗θ (t) + (1− p)}
1−δi , (3.16)
where θ is a vector of statistical parameters, and the functions S∗θ (t) and f
∗
θ (t) are identified
with these parameters. To simplify notation we stop writing index θ repeatedly unless for
emphasizing and remembering this.
This likelihood is derived from the fact that the probability of experiencing the event for
those individuals who are not censored at time t is pf ∗θ (t), and the probability of staying
alive up to time t for those individuals who have been censored at time t is pS∗θ (t) + (1− p).
The specification of S∗θ (t), or equivalently f
∗
θ (t), can be parametric or nonparametric, which
leads to parametric and nonparametric mixture models.
3.4 Parametric mixture models
Parametric mixture cure rate models are obtained by simply considering a parametric model
for S∗θ (t) in equation (3.15). The most frequently used parametric models for S
∗
θ (t) are
Weibull, logistic, and exponential.
3.4.1 Weibull and conditional logistic mixture model
The susceptibility variable, η, has been defined by ?. He divides individuals into two cohorts,
one cohort is those individuals who face by the event of interest during the follow-up, η = 1,
and another is those individuals who survive by the end of experiment, and these could have
either η = 0 or η = 1.
The term π(γ⊤w) has been used here as the cured fraction, p in equation (3.15) to empha-
size the dependency of cured fraction on some covariates, w. Obviously γ is the vector of
related covariate coefficients to be estimated. To connect the cure fraction with the vector
of covariates, a link function is needed. Logistic regression is an option for link function as
follows:
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P (η = 1|w) = π(γ⊤w) =
exp(γ⊤w)
1 + exp(γ⊤w)
. (3.17)
Also, to emphasize the possibility of a connection between survival time of individuals and
some covariates like vector z, the mixture model formulation which is introduced by equation
(3.15) can be reformulated with the following notation:
S(t|w, z) = 1− π(γ⊤w) + π(γ⊤w)S∗(t|z). (3.18)
In the above equation for time to event variable, T , two different parametric models have
been assumed, one for individuals who are susceptible and the other one for those who are
not susceptible. Consider the probability of survival for susceptible individuals (η = 1), with
covariate vector z, is obtained by Weibull distribution, Farewell (1982). The Weibull distri-
bution function is defined in (2.13), where λ = exp(−β⊤z) is replaced with scale parameters,
and vector β represents unknown regression coefficients. Note that the parameter λ differs
for each individual because of covariate the vector z.
We refer to the combination of (3.17) and Weibull distribution function as Weibull mixture
cure rate model.
Assume that no individual with η = 0 experience failure during the follow-up. The unknown
parameters are estimated using maximum likelihood. The probability of failure at time t
for an individual is P (η = 1|z)f(t|η = 1, z). If the individual has been followed completely
during the study, the probability of survival by the time t becomes
{1− P (η = 1|z)}+ P (η = 1|z)
∫ ∞
t
f ∗(s|η = 1, z)ds. (3.19)
The likelihood function has the form of equation (3.16), where S∗(t) =
∫∞
t f
∗(s|η = 1, z)ds,
and f ∗(t) is replaced by Weibull distribution function. The cured fraction, p, also is re-
placed by parametric model of equation (3.17). An iterative method, like Newton-Raphson,
is adopted to maximize the log likelihood function, numerically.
3.5 Nonparametric mixture models
In this section a nonparametric estimation is assumed for F ∗, the cumulative distribution
of the survival times for susceptible individuals. The first nonparametric model that crosses
the mind to fit on survival data is Kaplan-Meier estimator. In statistical modelling context
usually the aim is to examine the effects of multiple covariates on the response variable. In
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cure rate models, one of the goals is to investigate how other factors can affect the cured
fraction and the survival time of susceptible patients. Cox proportional hazard (CPH) model
is a well-known survival model to investigate the effect of covariates on survival time. The
following section aims to explain a nonparametric approach for mixture cure rate models,
using CPH model.
3.5.1 Proportional hazard mixture model
The material of this section is acquired from Peng and Dear (2000). To study a general
nonparametric mixture model, the CPH model can be a good choice for connecting failure
time to some covariates. Because CPH model is specifically appropriate for survival data and
relaxes the normality assumption. The EM algorithm is another tool that has been used for
estimating parameters in this method Dempster et al. (1977).
Again, suppose that z and w are two covariate vectors related to each individual, in which
the distribution of T ∗, and cured fraction, respectively, may depend on them.
For susceptibility indicator a model similar to equation (3.17) can be considered, and S∗(t|z)
is replaced with survival CPH function to model the effects of covariate z on the failure
distribution of susceptible individuals. The CPH model takes the following form:
h∗(t|z) = h∗0(t) exp(z
⊤β), (3.20)
in which h∗(t) is hazard function, and h∗0(t) is the baseline hazard function and can be any ar-
bitrary specified hazard function but not a function of z. This leads to S∗(t|Z) = S∗0(t)
exp(β⊤z)
as a model for survival function of susceptible individuals, where S∗0(t) = exp{−
∫ t
0 h
∗
0(s)ds}.
EM algorithm can be used to estimate γ in (3.17), and β in (3.20).
EM algorithm is an iterative method for finding locally maximum likelihood and for estimat-
ing parameters in a model. This algorithm has been applied usually when it is assumed there
are some unmeasured parameters in the dataset. These unmeasured parameters is sometimes
called missing values. This method consists of two steps, the E-step and the M-step. In the
E-step the aim is to find expectation of complete log-likelihood (as a function of missing
value) conditional on the observed values and estimated parameters in the previous itera-
tion, and in the M-step the goal is to find a new estimation for the parameters of the model
by maximization of the expectation of complete log-likelihood. For complete details of EM
29
algorithm on mixture models, see Dempster et al. (1977).
To use the EM algorithm, η is treated as the missing parameter, which is an indicator for
susceptibility. It is obvious that when δi = 1, i.e. censoring indicator is equal to 1, therefore
ηi = 1, which means individual ith is susceptible. If ith individual is censored, δi = 0, then
ηi is one or zero. Therefore η is partially missing information (or parameter); it could be
used to illustrate a new complete likelihood function for mixture cure model given η, and
observed variables.
Note that π(γ⊤wi) = P (ηi = 1|wi).
Let’s suppose O = (xi, δi,wi, zi) denotes the observed data for ith individual, i = 1, . . . , n,
and θ = (γ, β, S∗0) as unknown parameters to be estimated.
Given η and O the complete log-likelihood function is
ℓc(θ) = log
{
n∏
i=1
[
{π(γ⊤wi)f ∗(xi|zi)}ηi
]δi
× (3.21)
[
{1− π(γ⊤wi)}1−ηi{π(γ⊤wi)S∗(xi|zi)}ηi
]1−δi}
,
and the probability of being uncured for ith individual is
gi = P (ηi = 1|O, θ) = δi +
(1− δi)π(γ⊤wi)S∗(xi|zi)
1− π(γ⊤wi) + π(γ⊤wi)S∗(xi|zi)
. (3.22)
The first term on the right-hand side of equation (3.22) represents the probability of observing
failure when the individual is not censored, which is one (δi = 1). The second term is the
probability of susceptibility when the individual is censored at time xi.
Note that the probability of susceptibility for an individual with covariate vector wi and zi,
given that subject be censored, is equal to
P (ηi = 1|δi = 0) =
π(γ⊤wi)S∗(xi|zi)
1− π(γ⊤wi) + π(γ⊤wi)S∗(xi|zi)
.
For the E-step conditional expectation of the complete log-likelihood with respect to η at the
current estimates of F ∗(xi|zi) and π(γ⊤wi) is computed. Suppose the complete log-likelihood
function is split into two functions like below:
ℓc(θ) = ℓc1(γ) + ℓc2(β, S∗0).
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Indicator Eη(ℓc|O, θ) denotes the expectation of complete log-likelihood and can be written
as the sum of following equations:
E(ℓc1|O, γ) =
n∑
i=1
[
gi log{π(γ⊤wi)}+ (1− gi) log{1− π(γ⊤wi)}
]
, (3.23)
E(ℓc2|O, β, S∗0) =
n∑
i=1
[
gi log{S∗(xi|zi)}+ δi log{h∗(xi|zi)}
]
, (3.24)
where h∗(t) = f
∗(t)
S∗(t)
is the hazard function of susceptible individuals.
The next phase of the EM algorithm is the M-step. In this step equations (3.23) and (3.24)
are maximized with respect to θ for a fixed gi. In the E-step, the expectation of log-likelihood
is broken into two separate functions, (3.23) and (3.24). The equation (3.23) depends on the
unknown parameter γ only, and equation (3.24) contains only the unknown parameter β.
Therefore, the maximization step can be carried out by maximizing these two functions sep-
arately. Equation (3.23) can be maximized analytically, but maximizing equation (3.24) is
not as easy, because it depends on the relation between covariates and failure times. Equation
(3.20) represents how covariates vector z are connected to failure time. The only missing part
is the baseline hazard function, h∗0(t), in equation (3.20). Equivalently S
∗
0(t) can be specified
instead of h∗0(t), because when S
∗
0(t) is determined, h
∗
0(t) can be specified. In the following
we discuss the estimation of S∗0(t).
Let t∗(1), t
∗
(2), . . . , t
∗
(q) be the ordered distinct uncensored failure times. The set of δj tied
uncensored failures at t∗(j) is denoted by Dj . Let Ej be the set of individuals with censoring
time in [t∗(j), t
∗
(j+1)), j = 0, . . . , q, in which t
∗
(0) = 0, and t
∗
(q+1) =∞. Rj is the risk set at time
t∗(j) and contains those individuals who are alive and uncensored just prior to time t
∗
(j). Again,
let z(1), z(2), . . . , z(q) be the covariates related to t∗(1), t
∗
(2), . . . , t
∗
(q). Here, the final equation that
has been obtained in Peng and Dear (2000) is introduced briefly; for more details the reader
can refer to this paper. Equation (3.24) can be approximated by:
log
q∏
j=1
exp(β⊤sj)
{
∑
i∈Rj gi exp(β
⊤zi)}δj
, (3.25)
where sj =
∑
i∈Dj zi is the sum of covariates vector for individuals in Dj. Maximizing (3.24)
is equivalent to maximizing (3.25). This new equation involves the regression parameter β
but not the baseline hazard function, and it can be maximized numerically using Newton-
Raphson. The estimation for baseline survival function S∗0(t) is required as well; see details
in Peng and Dear (2000). The estimation of S∗0(t) based on information obtained from esti-
mating β, γ and gi is as follows:
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Sˆ∗0(t) = exp

− ∑
j:t∗
(j)
<t
dj∑
i∈Rj gi exp(β
⊤zi)

 . (3.26)
Here a pseudo code is given for the whole steps of this method.
1. Consider initial values for γ, β and S∗0(t), like γ0, β0 and S
∗
00(t) (S
∗
00(t) obtained by
injecting β0 in equation (3.26) ).
2. In jth iteration, find gi from equation (3.22), for each i ∈ 1, . . . , n, regarding to estimated
parameters in (j − 1)th iteration. Name it gji .
3. Insert gji and γ
(j−1), β(j−1) in equations (3.23), (3.25) and obtain γ(j), β(j).
4. In jth iteration S∗
(j)
0 (t) can be found by using β
(j) and gji in equation (3.26).
5. Steps 2 to 4 should be repeated until a predefined convergence criterion is verified.
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CHAPTER 4 CURE RATE MODELS: MODERN APPROACH
4.1 Introduction
Recent studies in cure rate models are more focused on semiparametric mixture and non-
mixture cure rate models. In this chapter some of the more recent studies in mixture and
non-mixture models are discussed.
4.2 Semiparametric models
While parametric models force to impose models on data generating process, up to finite
many unknown parameters, non-parametric methods are procedures that work rather with
minimal distributional assumptions. The semi-parametric approach is an alternative method
which tries to retain the strength of both parametric and nonparametric models: the effi-
ciency and interpretability of parametric models, and robustness of the nonparametric models
to departure from the underlying assumptions about the data generality mechanism. In the
following, some of the semiparametric mixture and non-mixture cure models are introduced.
4.2.1 Cure rate quantile regression mixture model
Most of the previous two-component mixture cure rate models are mean-based regression
models, which give an overall quantification for the central covariate effects. The method of
the current section is based on quantile regression. Quantile regression finds a better assess-
ment of covariate effects, especially when the cure fraction is high. To estimate both quantile
regression coefficients and cure fraction coefficients, martingale-based estimating equations
have been proposed in the literature (Wu and Yin (2013)). Two estimation methods have
been suggested for the cure rate parameters: one method is based on the iteration between
the cure rate parameters and the quantile regression coefficients, and the other method sep-
arates them by applying the nonparametric kernel smoothing technique.
To connect covariates with cured fraction again, the logistic regression of equation (3.17)
has been suggested. Equation (3.9) is used to represent the true failure time as a convex
combination of failure time of susceptible individuals, T ∗, and ∞ if the individual is non-
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susceptible. To connect T ∗ with covariates the following linear model can be postulated:
log T ∗ = β⊤z + ε, (4.1)
where z, is a vector of covariates related to T ∗, and the error ε may depend on z. The aim
is to model a set of quantiles of susceptible survival times. Assume τ ∈ (0, 1), according to
Wu and Yin (2013) the definition of τ th conditional quantile function is
QT ∗(τ |z) = inf {t : P (T ∗ ≤ t|z) ≥ τ} , (4.2)
and quantile regression model is given by
QT ∗(τ |z) = exp{z⊤β(τ)}, (4.3)
where β(τ) is an unknown vector of regression coefficients for each τ ∈ (0, 1). Now, the
estimation of the coefficients β and γ is required. At first the method for estimating β is
discussed, and then two different methods for estimating γ are explained.
By applying the martingale formulation of censored quantile regression in Peng and Huang
(2008), the following estimating function can be used to estimate β(τ). To find out more
about how this equation is obtained you can refer to Wu and Yin (2013).
Un(β, τ ; γ) = n−1
n∑
i=1
zi
{
(Ni[exp{z⊤i β(τ)}]−
∫ τ
0
I[xi ≥ exp{z⊤i β(τ)}]dH(u|wi)
}
, (4.4)
where,
Hγ(u|w) = − log(1− π(γTw)u) for, 0 ≤ u ≤ 1,
and Ni(t) = I(xi ≤ ci)I(xi ≤ t).
Let L indicates the duration of the study and τmax, the upper bound of the quantile levels
that can be estimated, be a constant in (0, 1). To ensure the identifiability for all regression
quantiles below τmax, it is required that τmax be smaller than infz F ∗(L|z). Here, L is the
duration of the follow-up time. The proof of this statement is given in Wu and Yin (2013).
Estimation of β(τ, γ), for a fixed τ and a fixed γ, can be obtained by solving the equation
Un(β, τ ; γ) = 0. Equivalently a grid-based estimation procedure to estimate β(τ, γ) is ob-
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tained by sequentially locating the minimizer of the following convex objective function (4.5).
We denote a partition over the interval [0, τmax] , as S = {0 ≡ τ0, . . . , τqn ≡ τmax}, where the
number of grid points qn is allowed to depend on n, the number of subjects. The estimation of
β(τj, γ) is needed, for j = 1, . . . , qn, by sequentially minimizing the following convex function:
Lj(b) =
n∑
i=1
∣∣∣δi log xi − δib⊤zi∣∣∣+
∣∣∣∣∣R∗ − b⊤
n∑
i=1
(−δizi)
∣∣∣∣∣+∣∣∣∣∣∣R∗ − b⊤
n∑
i=1

2zi
j−1∑
k=0
I
[
xi ≥ exp{z⊤i βˆ(τk, γ)}
]
{Hγ(τk+1|wi)−Hγ(τk|wi)}


∣∣∣∣∣∣ , (4.5)
where R∗ is a large number greater than 103(p+ 1)×max{
∑p
j=1 z
2
ij : 1 ≤ i ≤ n}.
Two methods have been proposed for estimating γ; the iterative method and the nonpara-
metric approach.
In Section 3.5.1 the probability of being susceptible for ith individual is given by equation
(3.22). Thus, equation (3.22) is adopted to construct an estimating equation for γ in iterative
approaches. Since P (ηi = 1|wi) = π(γ⊤wi), it follows that
E [wi{P (ηi = 1|O)− P (ηi = 1|wi)}] = 0.
The above equation leads to the following estimating function for γ:
Sn(γ, F ∗) = n−1
n∑
i=1
wi{1− π(γ⊤wi)}
1− π(γ⊤wi)F ∗(xi|zi)
{δi − π(γ⊤wi)F ∗(xi|zi)}. (4.6)
Consequently, equation (4.7), which is equivalent to equation (4.6), can be considered as an
estimating function for estimating γ. See Wu and Yin (2013).
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Rn(γ; β(.)) = n−1
n∑
i=1
∫ τmax
0
wi{1− π(γ⊤wi)}
1− π(γ⊤wi)u
[
dNi(exp{z⊤i β(u)})−
I[xi ≥ exp{z⊤i β(u)}]Hγ(du|wi)
]
. (4.7)
To solve equation Rn(γ; β(.)) = 0, the parameter vector β(.) should be known. An equivalent
equation for equation (4.7) is given below.
n−1
n∑
i=1
qn−1∑
k=0
wi
[
1− π(γ⊤wi)
1− π(γ⊤wi)(τk + τk+1)/2
δi× (4.8)
I[ exp{z⊤i βˆ(τk, γˆ
(m))} ≤ xi < exp{z⊤i βˆ(τk+1, γˆ
(m))}]−
I[xi ≥ exp{z⊤i βˆ(τk, γˆ
(m))}]
∫ τk+1
τk
1− π(γ⊤wi)
1− π(γ⊤wi)u
Hγ(du|wi)
]
= 0
Following is the algorithm for estimating γ, and β(.):
1. Choose an initial value γˆ(0) for γ.
2. At the mth iteration, set exp{z⊤i βˆ(τ0, γˆ
(m))} = 0 and obtain βˆ(τj , γˆ(m)), for j =
1, . . . , qn, by sequentially minimizing (4.5).
3. Obtain γˆ(m+1) by solving equation (4.8), using Newton-Raphson algorithm.
4. Repeat steps (2) and (3) to reach to a predetermined convergence criterion.
This algorithm may be sensitive to initial values. This issue has been discussed by Mao and Wang
(2010) for a class of proportional odds cure rate models. Also, the entanglement of βˆ(.), and
γˆ makes the derivation of asymptotic properties difficult. To solve these challenges another
nonparametric approach for estimating parameter γ has been introduced by Wu and Yin
(2013).
The approach suggested by these authors estimates γ and β separately. The function F ∗ in
(4.6) is replaced by a nonparametric estimator Fˆ ∗, and then γ is estimated accordingly. Also,
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a Nelson–Aalen type estimator is considered for the cumulative hazard function, Λ∗(t|z), of
susceptible individuals
Λˆ∗(t|z) =
∫ t
0
∑n
i=1Bni(z)dNi(u)∑n
k=1 I(xk ≥ u)wk(γˆ, Λˆ∗)Bnk(z)
, (4.9)
where
wk(γ,Λ∗) = δk + (1− δk)
π(γ⊤wk) exp{−Λ∗(xk|z)}
1− π(γ⊤wk) + π(γ⊤wk) exp{−Λ∗(xk|z)}
, (4.10)
and Bni(z) =
Kp{(z−zi)/hn}∑n
k=1
Kp{(z−zk)/hn}
. Here Kp(.) is a p-variate kernel function with p equal to
number of different covariates in z, and hn > 0 is the bandwidth converging to zero as n→ 0.
Note that Fˆ ∗(t|z) can be estimated by Fˆ ∗(t|z) = 1− exp(−Λˆ∗(t|z)). Following the nonpara-
metric approach is illustrated step by step.
At first an initial value for γ like γ0 is assumed, and then plug γ0 and wk = 1, for k = 1, . . . , n
in equation (4.9) to obtain Λˆ∗0(t|z) as the initial value for Λˆ∗(t|z). Then by plugging Λˆ∗0(t|z),
and γ0 into equation (4.10), w0k is obtained. At the m
th iteration we perform:
1. Plug wmk into (4.9) to obtain Λˆ
∗(m+1)(t|z).
2. Plug Λˆ∗(m+1)(t|z) into (4.6) and solve the equation by Newton-Raphson algorithm to
obtain γˆ(m+1).
3. Plug γˆ(m+1) and Λˆ∗(m+1)(t|z) into (4.10) to get w(m+1)k .
4. Repeat steps 1, 2, and 3 until a pre-set convergence criterion is met.
For some identifiability and computational problems, Λˆ∗(t|z) =∞ has been considered when
t is greater than the largest observed failure time. The resultant estimator which is obtained
from the above algorithm is denoted by γˆN , and is used to plug in equation (4.5), to obtain
βˆ(τ, γˆN).
Finally, consider that βˆI is obtained, as an estimate of β, and γˆI is an estimate of γ which has
been obtained by one of the above algorithms. Under some conditions, which are given in
Wu and Yin (2013), the resultant estimators are consistent in probability and have asymp-
totically normal distributions.
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4.2.2 Two groups trial with semiparametric method
The material of this section is adopted from Shen et al. (2007).
In this section a semi-parametric cure rate model is introduced to analyse data which specifi-
cally consist of two different treatment groups. Suppose the effect of two different treatments
is going to be studied by dividing the patients in two groups randomly, and applying each
treatment to each group separately. We call these two groups, cohort 1 and cohort 2. Here,
cohort 2 is the control group. The interest is to estimate the distribution of time to diagnosis
of the disease, and the incidence of the disease within each group. Suppose there are two
different cure rates and two different survival time distributions for each cohort. Consider
that B is a variable which takes value 1 if the individual belongs to cohort 1 and takes value 2
otherwise. Furthermore, p1 = P (η = 1|B = 1) and p2 = P (η = 1|B = 2) are the probability
of susceptibility for cohort 1 and cohort 2, respectively. Therefore, the probability of being
cured in each cohort is 1− p1 and 1− p2.
Suppose S∗1(t|η = 1) is the survival function for the time to disease diagnosis, conditional
on the ultimate occurrence of the disease in cohort 1. Consequently, S1(t) is an improper
survival function for cohort 1, which follows the mixture cure model of equation (3.15), with
p1 replacing p in this equation. Subsequently, the same formula applies for cohort 2 of patients
with S1 replacing S2, and S∗1 replacing S
∗
2 .
Mixture model in each group allows to study the distribution of time to disease diagnosis or
the probability of incidence in each group separately, but finding a pattern to fit the data or
connect the two groups of data together is needed. When the nonparametric discrete density
curves for the time to disease diagnosis in each group of data show similar shapes, but in
different scales for the two treatment groups, the change in the time to disease diagnosis
between the two cohorts could be shown by the natural logarithm of the two densities ratio
fitted in a specific form.
Suppose f ∗1 and f
∗
2 are the proper probability density functions of time-to-disease diagnostic
in cohort 1 and cohort 2 respectively. The following equation shows the connection between
these two probability density functions:
f ∗2 (t) = exp{α
⋆ + βh(t)}f ∗1 (t), (4.11)
where h is a specific function for transforming the observed time t, and α⋆ and β are a con-
stant and a vector of coefficients respectively. Note that α⋆ is a new notation to emphasize
difference between α⋆ and α which is introduced later.
The model (4.11) presents a natural logistic regression connection between cohort 1 and co-
hort 2, or equivalently giving the following equation.
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Note that in the following equations T represents the group of time-to-disease diagnostic in
both cohorts, and t represents a specific time-to-disease diagnostic.
P (B = 2|t) =
P (B = 2, T = t)
P (T = t)
=
P (B = 2, T = t)
P (T = t, B = 2) + P (T = t, B = 1)
=
P (B = 2)P (T = t|B = 2)
P (B = 1)P (T = t|B = 1) + P (B = 2)P (T = t|B = 2)
=
P (B = 2)f ∗2 (t)
P (B = 1)f ∗1 (t) + P (B = 2)f ∗2 (t)
=
P (B = 2) exp{α⋆ + βh(t)}f ∗1 (t)
P (B = 1)f ∗1 (t) + P (B = 2) exp{α⋆ + βh(t)}f ∗1 (t)
=
P (B=2)
P (B=1)
exp{α⋆ + βh(t)}
1 + P (B=2)
P (B=1)
exp{α⋆ + βh(t)}
.
Thus, if we consider α1 = α⋆ + log {
P (B=2)
P (B=1)
}, then P (B = 2|t) = exp{α1+βh(t)}
1+exp{α1+βh(t)}
, and it has
the form of logistic regression.
Model (4.11) with a proper choice of h provides a good fit to the data. This model needs
to be fitted to right-censored data with a cure rate fraction. In order to illustrate the full
likelihood function according to the model (4.11) for censored data, assume x1, . . . , xn0 are
the observed times in cohort 1 of patients and xn0+1, . . . , xn, n = n0 + n1, are observed time
in control group or cohort 2. Therefore,
L(θ) =
n0∏
i=1
{p1f
∗
1 (xi)}
δi{(1− p1) + p1S∗1(xi)}
1−δi× (4.12)
n∏
j=n0+1
{p2f
∗
2 (xj)}
δj{(1− p2) + p1S∗2(tj)}
1−δj ,
in which θ is statistical parameter vector related to f ∗1 (t), f
∗
2 (t), S
∗
1(t) and S
∗
2(t).
The equation is the full likelihood function for mixture cure rate models with two groups
sample datasets. In general, estimating the unknown parameters requires EM algorithm
or one of the MCMC algorithms which could be computationally expensive. Therefore, a
conditional estimating approach by generalizing the profile likelihood method is applied; see
Qin and Zhang (1997).
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An alternative method to the full likelihood maximization is based on estimating equations
conditional on the observed failure only (δ = 1). Suppose f1 represents the probability den-
sity function of T conditional on δ = 1 in the cohort 1 of patients, and f2 is the probability
density function of T conditional on δ = 1 in the cohort 2 of patients. So,
f1(t) = lim
∆t→0
P (∆t < T < t+∆t|δ = 1)
∆t
(4.13)
=
lim∆t→0
P (∆t<T<t+∆t,C>t|δ=1)
∆t
P (T < C)
(4.14)
=
p1f
∗
1 (t)H¯1(t)∫∞
0 p1f
∗
1 (v)H¯1(v)dv
(4.15)
=
f ∗1 (t)H¯1(t)
µ(f ∗1 , H1)
, (4.16)
where H¯1(t) is the survival function of censoring time variable C, and
µ(f ∗1 , H1) =
∫ ∞
0
p1f
∗
1 (v)H¯1(v)dv
is a constant with unknown quantities for f ∗1 and H1. The density f2(t) is the equivalent
definition of f1 for cohort 2 of patients. Thus,
f2(t) =
f ∗2 (t)H¯2(t)
µ(f ∗2 , H2)
.
Under the model (4.11),
f2(t)
f1(t)
= exp {α + βh(t) + ψ(t)}, (4.17)
where α = α⋆ + log {µ(f ∗1 , H1)− µ(f
∗
2 , H2)}, and ψ(t) = log H¯2(t)− log H¯1(t).
Let t∗1, . . . , t
∗
m0 , t
∗
m0+1, . . . , t
∗
m denote the observed time-to-disease diagnosis in cohort 1 and
cohort 2, among x1, . . . , xn0, and xn0+1, . . . , xn, where m = m0 +m1, and m0 and m1 are the
number of failures in cohort 1 and cohort 2. Suppose lcon is the corresponding conditional
log-likelihood:
ℓcon(α, β, F ∗) =
m∑
i=1
log f1(t∗i ) +
m∑
j=m0+1
{α + βh(t∗j) + ψ(t
∗
j )}. (4.18)
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The conditioning is over the following constraints:
m∑
i=1
f1(t∗i ) = 1, (4.19)
m∑
i=1
f1(t∗i ){exp(α + βh(t
∗
i ) + ψ(t
∗
i ))− 1} = 0. (4.20)
These two constraints are to guarantee that
∫
f1(x)dx = 1, and
∫
g1(x)dx = 1. When the
censoring distribution of two groups are the same, ψ(t∗) = 0. Therefore maximizing the
equation (4.18) is equivalent to maximizing the ordinary logistic regression likelihood, and
the estimators of α and β are consistent. But when ψ(t∗) 6= 0, the following score equations
hold for (α, β):
∂ℓcon
∂α
= m1 −
m∑
i=1
ρ exp {α + βh(t∗i ) + ψ(t
∗
i )}
1 + exp {α + βh(t∗i ) + ψ(t∗i )}
,
∂ℓcon
∂β
=
m∑
i=m0+1
h(t∗i )−
m∑
i=1
ρh(t∗i ) exp {α+ βh(t
∗
i ) + ψ(t
∗
i )}
1 + exp {α + βh(t∗i ) + ψ(t∗i )}
,
where ρ = m1/m0.
The estimate of (α, β) is obtained by solving the equations ∂lc
∂α
= 0 and ∂lc
∂β
= 0. These esti-
mators are unbiased and consistent (Shen et al., 2007). In general, ψ is unknown; therefore
it is replaced by its consistent estimator, ψˆ = log(Hˆ2) − log(Hˆ1), where Hˆ1 and Hˆ2 are the
Kaplan-Meier estimators for the survival functions of the censoring variables in cohort 1 and
cohort 2 of patients, respectively.
After obtaining (αˆ, βˆ), the other unknowns are estimated:
fˆ1(t∗i ) = m
−1
0 {1 + ρ exp{αˆ + βˆh(t
∗
i ) + ψˆ(t
∗
i )}
−1, (4.21)
fˆ2(t∗i ) = exp(αˆ + βˆh(t
∗
i ) + ψˆ(t
∗
i ))fˆ1(t
∗
i ). (4.22)
Since dF1(t) =
dF ∗1 (t)H¯1(t)
µ(f∗1 ,H1)
and
∫∞
0 dF
∗
1 (t) = 1, it follows that the constant µ can be estimated
by
µˆ(f ∗1 , H1) =
1∫
Hˆ−11 (t)dFˆ1(t)
(4.23)
=

 m∑
i=1
fˆ1(t∗i )
ˆ¯H1(t∗i )


−1
,
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where ˆ¯H1(t∗i ) = 1− Hˆ1(t
∗
i ).
Also, F ∗1 (t) can be estimated by Fˆ
∗
1 (t) = µˆ(f
∗
1 , H1)
∑m
i=1
ˆ¯H−11 (t∗i )fˆ1(t
∗
i )I(t
∗
i ≤ t), and in the
same way
Fˆ ∗2 (t) = µˆ(f
∗
2 , H2)
m∑
i=1
ˆ¯H−12 (t
∗
i )fˆ2(t
∗
i )I(t
∗
i ≤ t),
where
µˆ(f ∗2 , H2) =

 m∑
i=1
fˆ2(t∗i )
ˆ¯H2(t∗i )


−1
.
To estimate the cumulative incidence in each group, the non-parametric conventional Kaplan-
Meier estimator is suggested. Suppose 1 − F˜n0 and 1 − F˜n1 are survival Kaplan-Meier esti-
mators of cohort 1 and cohort 2 (F˜n0 is an estimator for F ). According to equation (3.3),
pˆ1 = F˜n0(t(n0)) and pˆ2 = F˜n1(t(n1)), where t(n0) and t(n1) are the last observed failure time
and censored time for cohort 1 and 2.
4.3 Non-mixture models
Another method for modelling time-to-event data is non-mixture cure models. Despite the
fact that standard cure rate model is more attractive and has been widely used, it has some
disadvantages such as it cannot have a proportional hazard structure; see Ming-Hui Chen
(1999). This disadvantage can be overcome with an alternative definition of cure rate model.
Although non-mixture cure models have attracted less attention compared to mixture cure
models, they remain useful in a number of particular cases, especially those related to cancer
studies.
Among parametric, nonparametric, and semi-parametric methods for developing the non-
mixture cure models, it seems semi-parametric methods are applied more often. Therefore,
it is adequate to explain one of the semi-parametric models to illustrate the rationale behind
this modelling technique. In this section an alternative approach to cure models is introduced
and resimulate the method of Ming-Hui Chen (1999).
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4.3.1 Semi-Parametric non-mixture models
In non-mixture modelling formulation, the latent variable, η, of mixture model is replaced
by a new unknown variable N , with a new definition. Suppose N denotes the number of
defective tumor cells for an individual in the population which have been left active after the
initial treatment. A defective tumor cell is a tumor cell which has the potential of metasta-
sizing. Consider N has a Poisson distribution with parameter µ. Suppose Ti is the random
time variable for the ith defective tumor cell to produce detectable metastatic disease. Given
N , the random variables Ti, i = 1, 2, . . . are assumed to be independent and identically dis-
tributed with a common distribution function FT (t) that does not depend on N . The time
to relapse of cancer can be defined by random variable X = min{Ti, 0 ≤ i ≤ N}, where
P (T0 = ∞) = 1. Note that in this section T and X have slightly different definitions from
the previous one, and T0 represents time to detectable metastatic when there is no defective
tumor cell. The survival function for X is given by
S(t) = P (no metastatic cancer by time t) = P (N = 0) + P (T1 > t, . . . , TN > t,N ≥ 1).
After some algebra we have:
S(t) = exp(−µ) +
∞∑
k=1
ST (y)k
µk
k!
exp(−µ)
= exp(−µ+ µST (t)) (4.24)
= exp(−µFT (t)),
where S(t) = exp(−µFT (t)) is an improper survival function, because S(∞) = exp(−µ) > 0.
Therefore the cure fraction is S(∞) ≡ P (N = 0) = exp(−µ). This model is suitable for
survival data that include cured fraction. According to formulation (4.24),
f(t) = µfT (t) exp {−µFT (t)} (4.25)
and
h(t) = µfT (t). (4.26)
Here, f(t) is not a proper probability density, but fT (t) is. The hazard function obtained by
this formulation has the proportional hazard structure. This form of the hazard function is
more common in analysis of survival data than the one from standard cure model in case of
application and computation.
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The survival function for the susceptible population is given by
S∗(t) = P (X > t|N ≥ 1)
=
exp(−µFT (t))− exp(−µ)
1− exp(−µ)
. (4.27)
Because S∗(0) = 1 and S∗(∞) = 0, it follows that S∗(t) is a proper survival function. The
survival density and hazard function for the susceptible fraction of individuals are
f ∗(t) = −
d
dt
S∗(t)
=
[exp{−µFT (t)}
1− exp(−µ)
]
µfT (t) (4.28)
and
h∗(t) =
h(t) exp {−µFT (t)}
exp {−µFT (t)} − exp(−µ)
=
h(t)
P (X <∞|X > t)
. (4.29)
According to the equation (4.27) and equation (4.24), it can be shown that
S(t) = exp(−µ) + {1− exp(−µ)}S∗(t). (4.30)
By comparing equation (3.15) and equation (4.30), it can be seen that there is a natural
connection between standard cure model and non-mixture cure model. In other words one
may reconstruct equation (3.15) from equation (4.30) replacing p by exp(−µ).
We incorporate the covariates in the model (4.24) through µ according to the relationship µ =
exp(z⊤β), where z is a p×1 vector of covariates and β is a p×1 vector of regression coefficients.
By this relationship between covariates and cured fraction, the regression coefficients become
interpretable for cured and non-cured fractions. For cured fraction, the negative sign of
regression coefficient leads to a larger cure fraction for positive covariates value. For the non-
cured fraction the regression coefficients affect the hazard function in (4.29). For example, a
negative regression coefficient leads to a larger hazard, for a positive covariate.
The likelihood function can be constructed as follows. Suppose n individuals are under the
study, and let Ni denote the number of metastasis-competent tumor cells for ith individual.
Further, suppose that Ni’s are Poisson random variables with mean µ, for i = 1, 2, . . . , n, and
Ni’s are not observed. Let Ti1, Ti2, . . . , Ti,Ni, be i.i.d. time-to-metastasis for the i
th individual,
which are unobserved and have the same proper cumulative distribution function, FT (.). We
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will specify a parametric form for FT (.), such as Weibull distribution. This distribution has
its indexing parameter vector, ψ, thus there are two new notations: FT (.|ψ) and ST (.|ψ).
By assuming Weibull distribution for FT (.|ψ), the indexing parameter vector is ψ = (α, λ)⊤,
where α is the shape parameter and λ is the scale parameter of the Weibull distribution. Our
observed data is O = (n, x, δ), where xi denotes the observed survival time for ith subject,
and δi denotes the censoring indicator for ith individual, i = 1, 2, . . . , n. The complete data is
given by D = (n, x, δ, N), where N is an unobserved variable. The complete data likelihood
function of the parameter θ = (ψ, β) can be written as
L(θ|D) =
[ n∏
i=1
ST (xi|ψ)Ni−δi{NifT (xi|ψ)}δi
]
× exp
[
n∑
i=1
{Niziβi − log(Ni!)− exp(z⊤i β)}
]
.
(4.31)
Since the covariates are weighted in this model through µ, this implies that each individ-
ual has different cure rates, µi ≡ exp(z⊤i β). To estimate the corresponding parameters in
this likelihood function there are several methods like the EM algorithm and the MCMC
methods. In Ming-Hui Chen (1999), one of the MCMC methods is implemented. To run the
MCMC method of Ming-Hui Chen (1999), one needs to sample from the following complete
conditional posterior distributions:
i) Sample β,N |ψ,O.
ii) Sample ψ|β,N,O.
By applying the collapsed Gibbs procedure, we have:
[β,N |ψ,O] = [β|ψ,O][N |β, ψ,O]. (4.32)
Briefly the MCMC algorithm samples from the posterior is:
1. Sample Ni ∼ Pois
{
ST (xi|ψ) exp(z⊤i β)
}
+ δi.
(In this step we add δi to the Poison distribution, because when δi = 1, i.e. failure
happened for subject ith, then the number of defective cells should be at least 1.)
2. Sample β from the following conditional posterior density:
π[β|ψ,O] ∝ exp
{
n∑
i=1
[δiz⊤i β − exp(z
⊤
i β){1− ST (xi|ψ)}]
}
× π0(θ).
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3. Sample ψ = (α, λ)⊤ from the following joint conditional posterior density:
π[ψ|β,N,O] ∼
n∏
i=1
ST (xi|ψ)Ni−δifT (xi|ψ)δi × π0(θ),
where π0(θ) is the initial prior distribution for θ = (β, ψ). Furthermore, assume that π0(θ)
is log-concave. A gamma prior for α with a small shape and scale parameters, and an inde-
pendent normal prior for λ with mean 0 and variance c are often suggested. In most cases
π[ψ|β,N,O] and π[β|ψ,O] are log-concave in each component of β and ψ respectively, there-
fore the adaptive rejection algorithm can be used to sample from these posterior distributions
efficiently. This model is fast in convergence and is compatible with cancer datasets.
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CHAPTER 5 SIMULATION
5.1 Introduction
In this section we conduct simulations to test three of the cure rate models proposed in
the thesis. Even though cure rate models have been used in different areas ranging from
medicine to reliability, there is only a few computational packages available for fitting these
models. There are two R packages called smcure, and NPHMC, currently available on CRAN.
The smcure fits semi-parametric proportional hazard mixture cure rate models and semi-
parametric accelerated failure time mixture cure rate models. The NPHMC can helps simulate
cure datasets. For more recent models such as mixture quantile regression cure models, two
groups mixture cure models, and non-mixture cure models there is no package to ease data
simulation.
Here, three classes of semi-parametric models, namely mixture quantile regression cure rate
model, two groups mixture model, and non-mixture model are fitted and then a Monte Carlo
study is conducted for each model to examine their accuracy.
5.1.1 Cure rate quantile regression model
To study finite-sample performance of the quantile regression method, we run the set up
of Wu and Yin (2013). The simulation setting is briefly explained bellow, see Wu and Yin
(2013) for more details.
As discussed in Section 4.2.1, two groups of covariates are simulated. The matrix w is the
covariates associated with susceptibility of each individual and the matrix z is covariates
related to the survival time of susceptible individuals. The matrix z includes a two columns.
One column is a vector of ones, and other column is z, simulated from Bernoulli(0.5). We
set z = w, γ0 = 1 and γ1 = −0.5 to generate susceptibility indicator η from equation (3.17).
Failure time of susceptible individuals is simulated from the following log-transformed linear
model
logT ∗ = b0z + (1 + z)ε,
in which b0 = −1, and (1+z)ε is the error term. Given z the corresponding quantile regression
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model of equation 4.3 is:
QT ∗(τ |z) = exp(β0(τ) + β1(τ)z),
where β0(τ) = Qε(τ), β1(τ) = b0 + Qε(τ) and Qε(τ) is the τ th quantile regression of ε.
Censoring time for each individual is simulated from Unif(0, L + 2) if z < 0.5, and from
Unif(1, L + 2) if z ≥ 0.5, where L is the duration of the study. We simulated two sets of
individuals, one with n = 100 and the other with n = 400, with the Monte Carlo replication
of 1000 times. The bootstrap method for estimation of standard errors was used, with 200
samples. The results of simulations is given in Tables 5.1 to 5.2. The R code related to this
simulation is given in Appendix A
Table 5.1 Estimation of γ, under the iterative quantile regression method. The error term
for the following simulation is the standard normal distribution. True indicates true value
of the parameter. EST indicates estimated value. SE shows standard error, MSE indicates
mean square error, and Bias shows the bias for the estimation.
n = 100 n = 400
True value EST(SE) MSE Bias EST(SE) MSE Bias
γ0 = 1 0.8(0.22) 0.07 0.15 0.8(0.32) 0.11 0.11
γ1 = −0.5 −0.4(0.13) 0.02 −0.02 −0.5(0.25) 0.06 0.03
Table 5.2 Simulation results for cure rate quantile regression. This table shows the estimation
of quantile coefficients for different τ ’s, in different simulation sets.
n = 100 n = 400
τ True value EST(SE) MSE Bias EST(SE) MSE Bias
0.2 β0 = −1.17 −1.9(0.23) 0.60 0.74 −1.3(0.34) 0.16 0.21
0.4 β0 = −0.17 0(0.18) 0.04 −0.1 −0.2(0.25) 0.06 0.03
0.6 β0 = 0.15 0.2(0.16) 0.03 −0.05 0.2(0.40) 0.16 −0.03
0.2 β1 = −2.17 −2.5(0.31) 0.21 0.34 −2.3(0.43) 0.22 0.21
0.4 β1 = −1.17 −0.9(0.26) 0.10 −0.19 −1.3(0.38) 0.17 0.16
0.6 β1 = −0.85 −1.2(0.17) 0.15 0.35 −0.5(0.27) 0.19 −0.34
Proposed cure rate quantile has 28% of non-convergence cases on average; see Wu and Yin
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(2013). Implementing quantile method requires extensive coding skill and there is no ready-
to-use package to fit this method. This iterative approach is relatively unstable and sensitive
to initial values.
5.1.2 Two groups mixture model
This simulation set up is motivated from Shen et al. (2007). In this simulation study the
point estimators and their standard error of α and β are estimated under model 4.11 when
h(t) = t. The p1 and p2 are estimated non-parametrically. Simulation is repeated with 1000
Monte Carlo replications with sample size 100 or 400.
We set p1 = 0.2 or 0.3 and p2 = 0.2 as true values for p1 and p2. We assumed that f ∗(t),
the distribution of failure times for group 1 of patients, is an exponential distribution with
mean ω. Censoring times for both groups have been generated from the same uniform dis-
tribution. The functions g∗ and f ∗ are computed according to the model 4.11, so g∗ is also
an exponential distribution with mean ν; then,
α = log(ω)− log(ν),
β = 1/ω − 1/ν.
We set ω = 1.5 and ν = 1.5, 2.5, 3; then we obtain different combinations of α, β to use as
the true values. The results of this simulation are presented in Table 5.3. The R codes related
to this simulation is given in Appendix B.
5.2 Non-mixture models
As in Chapter 4 the cured probability for non-mixture models is obtained from the following
equation:
p = exp{− exp(z⊤β)},
and depends on each individual. Another simulation is performed, once with n = 100, and
another time with n = 400 for non-mixture models. z1 is simulated from standard normal
distribution. Both parameters β0 and β1 are assumed equal to 1. The cure probability for
each individual is simulated from equation pi = exp(−µi), where pi is the cured probability
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for the ith subject, i = 1, . . . , n. If FT (t) is known, then survival time for each individual is
S(t) = exp(−µFT (t)). (5.1)
The U = FT (t) is simulated with uniform(0,1), then from the equation (5.1) the value of
S(t) is obtained. Suppose the survival probability of each individual is Weibull distribution
with the shape parameter equal to 1 and the scale parameter equal to exp(−1.5). Then the
survival time for each individual is calculated by using the inverse of Weibull distribution
function. Censoring indicator for each individual is defined by I(Ui ≤ Pi).
The MCMC algorithm, of Chapter (4), is iterated 2000 times with 1000 burning samples.
Table 5.4 shows that the estimates of parameters in non-mixture model have quite smaller
variances compared to standard cure rate models. The R codes related to this simulation is
given in Appendix C.
Table 5.4 The result of fitting a non-mixture cure model on simulated data. Censoring
rate in this case is approximatly between 0.40% to 0.70%, and the link function is equal to
p = exp(− exp(z⊤β)).
n = 100 n = 400
True value EST(SE) MSE Bias EST(SE) MSE Bias
β0 = 1 0.8(0.18) 0.05 0.14 0.9(0.09) 0.01 0.09
β1 = 1 1(0.16) 0.04 0.16 1(0.09) 0.01 −0.08
We have repeated the simulation sets of the original articles for each proposed model in
Chapter 4. The results of Table 5.1, Table 5.2, Table 5.3, and Table 5.4 show that imple-
mentation of these models have results close to original papers. The calculated variance for
parameters in each simulation set becomes smaller as the sample size increases, which implies
consistency of parameters in each model.
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Table 5.3 Parameter estimation for two groups mixture cure rate model. Here ω = 1.5 for
all sets.
n1 = n2 = 100 n1 = n2 = 400
True value EST(SE) MSE Bias EST(SE) MSE Bias
p
1
=
0.2
ν
=
1.5
α = 0 0(0.02) 0.05 −0.23 0(0.01) 0 0.001
β = 0 0(0.11) 0.012 0 0(0.07) 0.005 0
p1 = 0.2 0.2(0.09) 0.01 −0.02 0.2(0.05) 0.003 −0.02
p2 = 0.2 0.2(0.1) 0.012 −0.05 0.2(0.06) 0.005 −0.04
ν
=
2.5
α = −0.512 −0.5(0.34) 0.12 0.04 −0.5(0.17) 0.03 0.03
β = 0.267 0.2(0.38) 0.14 −0.01 0.2(0.32) 0.10 −0.01
p1 = 0.2 0.2(0.09) 0.01 −0.007 0.2(0.08) 0.01 −0.01
p2 = 0.2 0.2(0.13) 0.02 −0.06 0.2(0.1) 0.01 −0.05
ν
=
3
α = −0.693 −0.7(0.49) 0.24 0.07 −0.7(0.36) 0.13 0.05
β = 0.333 0.3(0.08) 0.006 0.01 0.3(0.04) 0.002 −0.016
p1 = 0.2 0.2(0.06) 0.003 −0.003 0.1(0.04) 0.002 0.015
p2 = 0.2 0.2(0.12) 0.02 −0.065 0.1(0.08) 0.007 0.022
p
1
=
0.3
ν
=
1.5
α = 0 0(0.06) 0.005 −0.04 0(0.05) 0.003 −0.03
β = 0 0(0.28) 0.08 0.027 0(0.24) 0.06 0.02
p1 = 0.3 0.3(0.15) 0.024 −0.04 0.3(0.09) 0.01 −0.04
p2 = 0.2 0.2(0.08) 0.008 −0.04 0.2(0.07) 0.005 0.01
ν
=
2.5
α = −0.512 −0.5(0.29) 0.08 0.02 −0.5(0.25) 0.06 0.04
β = 0.267 0.2(0.41) 0.17 0.004 0.2(0.39) 0.15 0
p1 = 0.3 0.3(0.15) 0.025 −0.05 0.3(0.12) 0.016 −0.05
p2 = 0.2 0.2(0.08) 0.01 −0.031 0.2(0.05) 0 −0.03
ν
=
3
α = −0.693 −0.7(0.24) 0.06 0.07 −0.7(0.21) 0.048 0.06
β = 0.333 0.3(0.37) 0.14 −0.013 0.3(0.3) 0.1 −0.011
p1 = 0.3 0.3(0.1) 0.012 −0.05 0.3(0.07) 0.007 −0.05
p2 = 0.2 0.1(0.07) 0.005 0.022 0.2(0.04) 0.002 −0.02
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CHAPTER 6 APPLICATION
6.1 Data summary
In this chapter cure rate models of Chapter 3 and Chapter 4 are fitted to Bone Marrow
Transplantation (BMT) dataset obtained from a study on 137 leukemia patients. Bone mar-
row transplantation is one of the most common remedies for critical leukemia patients. A
successful transplantation may depend on several factors, such as patient or donor age, sex,
status of disease of the patient at the time of transplantation, patient’s time of diagnostic,
patient’s post-transplantation recovery history, etc. Transplantation is considered to be un-
successful when the patient’s leukemia relapses or when the patient dies. The goal of this
study is to illustrate the probability of relapse or death for the patients who were under bone
marrow transplantation therapy.
The data were collected between March 1, 1984 to June 30, 1989, and is used by Copelan et al.
(1991) to study the effects of pre-transplantation treatment on failure rate of transplanta-
tion. John P. Klein (1990) also used this dataset to develop a partially parametric estimator
of survival data. The patients from age 7 to 55 were treated with allergenic bone marrow
transplantation at five separate hospitals in Australia and the United States. Allergenic bone
marrow transplantation (BMT) following high-dose chemotherapy and total body irradiation
(TBI) cures many patients with acute myelocytic leukemia (AML). All donors were siblings
of recipients.
Different preparation regimes for transplant were applied to each patient. This results in var-
ious factors affecting the transplantation process. The dataset contains 22 variables, of which
10 variables report one potential risk factor. These risk factors increase a person’s chance
of developing a disease. The rest of the variables indicate different preparation process for
every patient, time-to-event variables, and failures indicators. The risk factor group reports
status of disease and different preparation regimes applied to different patients before the
surgery. The group equals 1 for acute Lymphocytic Leukemia (ALL), containing 38 patients.
The group equals 2 for low risk acute Lymphocytic Leukemia which consists of 54 patients.
The group equals 3 for high risk acute Lymphocytic Leukemia with 45 patients. The survival
time t, in days, indicates the shortest of the times to death, relapse or date of the most
recent follow-up time for each patient. The variable d is the patient failure indicator. This is
another categorical variable which takes value 1 if the patient is dead or had disease relapse,
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and equals 0 if patient survived by the end of the study. Some other factors, like age and sex
of the patients and donors, waiting time to transplant in days, are also recorded.
Among 137 patients in this study, 82 patients died or relapsed (the rate of failure in overall
groups are about 60%). For group ALL, there were 24 failures (63%), for group AML low
risk there were 25 failures (46%), and for group AML high risk there were 34 failures (75%).
6.2 Survival models
The response variable in this dataset is time to death or relapse, and the dataset contains
censored individuals. As the first step in analysis, Kaplan-Meier estimator is calculated to
provide an overall idea about the survival function of the population. Then, the effects of
various potential risk factors are estimated using Cox regression. Covariates highly correlated
with the survival time have mostly been selected.
As developed in Chapter 2, Kaplan-Meier estimator is a non-parametric method for esti-
mating survival probability of each individual up to certain time. Figure 6.1 shows that the
survival probability for low risk group of patients is higher than the high risk group of patients
as expected. At the beginning of the study, patients who are in AML high risk group have
higher risk of mortality and relapse. Patients in AML low risk group have greater probability
of survival. Figure 6.1 shows that All group of patients and AML high risk group of patients
have flat survival curve after 700 days. This means no more deaths are observed for these
patients after some point.
In Figure 6.2, the cumulative hazard function for each group of patients is illustrated. This
plot demonstrates AML high risk group of patients have higher risk of death during this trial.
6.2.1 Cox proportional hazard model
To examine the effects of covariates on the outcome (which is survival time for each individ-
ual) the Cox proportional hazard model is applied. There are ten variables in the dataset and
fitting advanced cure models with all 10 variables is complicated. Among all the covariates
the two which have the highest correlation with the outcome variable are selected for our
analysis of the data.
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Figure 6.1 Kaplan-Meier estimate for each group of patients in BMT dataset.
Let (z1, . . . z10) denote the vector of covariates where z1 and z2 are respectively the age of
the patient and the age of the donor. The donor-recipient age has a clear effect on the
survival time of recipient in transplantation surgeries (Douglas et al., 2004). We add another
covariate to capture the interaction between donor age and recipient age. The z12 is the
multiplicative variable of z1 and z2 which can possibly capture the interaction between these
two variables. This multiplicative variable is also added to the Cox proportional model. The
most significant variable that has smaller p-value in fitted model is z12. Therefore, z12 has
been considered as one of the covariates. Cox proportional model is fitted again, this time
with all variables except z12, z1 and z2. These three variables have been removed from Cox
proportional model to find out another risk factor most correlated with the survival time.
The variable with the second smallest p-value is z8 which is an indicator for French-American-
British (FAB) classifications of each patient. Therefore, z8 and z12 were chosen to be the two
covariates to contribute in the rest of the analysis. The Cox proportional hazard model with
two covariates z12 and z8 is
h(t|Z) ∼ h0(t) exp(group+ z12 + z8). (6.1)
Among the three variables, group was not significant; however, this variable has been kept
54
0 500 1000 1500 2000 2500
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
1.
2
1.
4
cumulative hazards for three groups of patients
time
cu
m
u
la
tiv
e 
ha
za
rd
ALL
AML Low Risk
AML High Risk
Figure 6.2 Cumulative hazard estimate for each group of patients in BMT dataset.
in the model for the future investigations.
6.3 Cure rate models
Cure rate models seem reasonable for these data, since we observe a long tail in Kaplan-Meier
curve presented in Figure 6.1 for patients who are in group ALL and AML high risk. The
first step in analysing cure rate models, as has been mentioned in Chapter 3, is to test the
possibility of having a cured fraction in the dataset. In the next section preliminary tests are
conducted for testing existence of a cure rate fraction.
6.3.1 Preliminary tests
There are two important questions that should be investigated before fitting any cure rate
model on a dataset. As it has been explained comprehensively in Chapter 3, the first question
is whether there is any cured fraction in the population, and the second question is whether
the follow-up time is long enough.
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Table 6.1 Estimating the effect of z1, z2, z8 and z12 using Cox model.
p-value Confidence Interval
group < 0.01 (0.7, 1.4)
z12 0.0003 (1.001, 1.005)
z8 0.01 (1.1, 3.1)
To answer the first question, pˆn should be estimated. Largest observed survival time in each
group of patients, t(n), are 2081, 2569 and 2640 days for group AML low risk, ALL, and AML
high risk respectively. So, pˆn for each group of patients is: 0.363, 0.456 and 0.24, and the
number of observations in each group is 37, 54 and 46, respectively. From Maller and Zhou
(1996), cα for α = 5% (or 10%) is always greater than 0.53, therefore the significance level is
always below the cut-off value. Therefore, H01 of equation (3.4) is rejected and we conclude
that there is a cured sub-population in all three groups of patients.
The answer to the second question has been discussed extensively in Section 3.2.2. The
statistic that we used for the statistical test is qn defined in equation (3.6). We computed
qn for each group of patients in the dataset. The results are 1, 0.018 and 1 for group AML
low risk, ALL and AML high risk respectively. Considering the number of patients in each
group, the simulated thresholds for statistics qn are above the 0.02 under significance level of
0.5% (or 0.10%) for group ALL and AML high risk, see Maller and Zhou (1996).
From the above discussion and with regards to discussion in Section 3.2.2, we accept H02 in
equation (3.5) under significance level of 0.5% (or 0.10%) for group ALL and AML high risk
of patients. Therefore, we conclude that the follow-up time is statistically long enough for
group ALL and AML high risk, but not for group AML low risk of patients.
6.3.2 Mixture models
Different types of parametric and non-parametric mixture cure rate models were discussed
in Chapter 3 and Chapter 4. In this section proportional hazard mixture model is fitted to
the BMT dataset. Functions related to proportional hazard mixture model are available in
packages smcure in R; see Cai et al. (2012). In addition, three of the more advanced mixture
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models that have been investigated in simulation studies in Chapter 5 are applied to the
BMT dataset.
In Section 3.5.1 theory and methodology of proportional hazard mixture cure rate model are
discussed. Such models are fitted on the BMT dataset. Fitting proportional hazard mixture
cure rate model on the dataset is easy and fast due to the availability of package smcure in R.
The variables in the model are z12 and z8. The same variables have been used to model cured
fraction and survival probability. The estimated results for coefficients and p-values are given
in Table 6.2 and Table 6.3. Formulation of proportional hazard mixture model in package
smcure does not include intercept for survival probability.
Table 6.2 Result of Cox proportional hazard cure rate model for ALL group, using package
smcure in R.
Survival parameters Cure parameters
Coefficient Est(CV) p-value Est(CV) p-value
Intercept − − 1.20(1.89) 0.52
z12 0.27(0.40) 0.50 0.24(0.36) 0.66
z8 0.36(1.0) 0.71 −1.13(1.62) 0.48
Table 6.3 Result of Cox proportional hazard cure model for AML high risk group, using
package smcure in R.
Survival parameters Cure parameters
Coefficient Est(CV) p-value Est(CV) p-value
Intercept − − 1.20(0.43) 0.01
z12 0.03(0.19) 0.88 −0.02(0.42) 0.96
z8 −0.14(0.36) 0.70 −0.17(0.90) 0.85
The null hypothesis cannot be rejected for neither group implying that z12 and z8 have no
effects. Given that there are only 38 patients in ALL group and 45 in AML high risk, such
results are not reliable. In the next section we apply more advanced cure rate models. The
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same covariates are used to see whether the selected covariates have any effects on the survival
time.
The cure rate quantile regression model in 4.2.1 and semi-parametric cure model for two
groups trials in 4.2.2 have been fitted on bone marrow transplantation (BMT) dataset in
this section. The covariates of interest are z12 and z8 which have been used in section 6.3.2.
These covariates are used both for survival probability and cure rate estimations. Patients in
groups ALL and AML high risk are involved in this study. We have generated 200 bootstrap
samples for estimating variance and p-value.
The coefficient of variation (CV) is used instead of standard error in the following tables
because standard errors for most of the parameter estimations are large, and estimations are
not significant in these cases. Then we used CV to be able to compare relative standard error
to parameter estimation.
Table 6.4 β0(τ): Parameter estimation using cure rate quantile regression for group ALL,
and AML high risk of patients.
Model parameters ALL Model parameters AML high risk
Est(CV) p-value Est(CV) p-value
τ = 0.2 3.83(0.12) 0.12 3.54(0.24) 0.33
τ = 0.4 5.23(0.13) 0.38 3.79(0.1) 0.28
τ = 0.6 5.38(0.1) 0.2 4.28(0.08) 0.22
γ0 13.37(0.57) 0.68 20(0.54) 0.14
6.3.3 Non-mixture model
Results in Table 6.7 show that semi-parametric two groups trial method fits the data well.
It seems semi-parametric two groups trials is a good model for small datasets. While β has
been estimated equal to zero which implies that log ratio of two density functions for each
group, according to model described in Section 4.2.2, is constant. The estimated π’s are close
to the failure rate in each group (failure rates are 63%, and 75% for groups ALL and AML
high risk of patients respectively). Since the scope of study is small, it sounds reasonable to
repeat the study with larger dataset to validate the findings.
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Table 6.5 β1(τ): Parameter estimation using cure rate quantile regression for group ALL,
and AML high risk of patients. The SE/µ is coefficient of variance.
Model parameters ALL Model parameters AML high risk
Est(CV) p-value Est(CV) p-value
τ = 0.2 −1.2(−0.88) 0.3 −0.13(−113.21) 0.2
τ = 0.4 −0.26(−1.04) 0.4 −0.1(−9.77) 0.2
τ = 0.6 −0.33(−1.05) 0.22 −0.09(−9.9) 0.24
γ1 −0.76(2.82) 0.78 12.5(−7.12) 0.12
Table 6.6 β2(τ): Parameter estimation using cure rate quantile regression for group ALL and
AML high risk of patients. The CV is coefficient of variation.
Model parameters ALL Model parameters AML high risk
Est(CV) p-value Est(CV) p-value
τ = 0.2 0.47(9.3) 0.18 1.13(0.6) 0.31
τ = 0.4 −0.61(9.91) 0.68 0.95(0.51) 0.28
τ = 0.6 −0.72(6.47) 1 0.5(0.66) 0.3
γ2 0.6(0.66) 0.65 8.94(0.73) 0.11
Table 6.7 Results of the analysis using semi-parametric two groups mixture cure model for
groups ALL and AML high risk group.
Parameter Est(CV) p-value
α 0.54(0.95) 0.03
β 0.00(−0.56) 0.04
p1 0.65(0.12) 0.001
p2 0.76(0.08) 0.001
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Table 6.8 Results of the analysis using the non-mixture cure rate model for ALL and AML
high risk of patients.
Model parameters group ALL Model parameters group AML high risk
Parameter Est(CV) p-value Est(CV) p-value
0.1(2.26) 0.25 0.28(0.87) 0.36
β1 −0.55(−0.8) 0.49 −0.22(−1.99) 0.55
β2 0.39(0.72) 0.28 −0.07(−2.61) 0.34
α −0.17(−1.03) 0.38 −0.08(−1.11) 0.53
λ −5.59(−0.03) 0.00 −5.32(−0.03) 0.00
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CHAPTER 7 CONCLUSION
In this chapter, we present a synthesis of the study of cure rate models developed throughout
the thesis. We also recapitulate on the simulation studies that we have conducted, and finally
we conclude about what could be done as future research.
7.1 Synthesis of cure rate models
Although cure rate models have been broadly studied for decades and many applications
have been reported, the scientific literature lacks studies that collect and analyse multiple
research studies or papers related to the topic. The current thesis provides an overview for
modelling the time-to-event data with cured fraction. We presented a summary on the early
approaches as well as some of recent works on cure rate models, which allow the reader to
have an overall understanding about the topic and different methods in cure rate models.
We discussed both mixture cure rate models and non-mixture cure rate models. The models
explained under mixture cure rate comprised proportional hazard mixture cure rate model,
quantile regression mixture cure rate model, and two groups trial mixture cure rate model.
The non-mixture cure rate model consists of an application of cure rate model with bayesian
approach for cancer data. All these models help to investigate different methods to adding
covariates and the impacts of these covariates in fitting mixture cure rate and non-mixture
cure rate models.
Each proposed model has different advantages and disadvantages. The proportional haz-
ard mixture cure rate model keeps all the advantages of regular proportional odds model
for survival analysis. For example we can still fit proportional hazard mixture cure rate
model on survival data with cured fraction without assuming a parametric model for sur-
vival time of subjects. While most of the cure rate models provide mean-based assessment
for analysing survival time and effects of covariates on survival time, the quantile regression
mixture cure rate model provides assessment for different quantiles of survival time. There-
fore, with quantile regression mixture models we can have a better understanding of trend
of covariates effects on survival times. We discussed another mixture cure rate model which
provides a semi-parametric model for survival data with cured fraction when we have two
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groups of patients. This model assumes a semi-parametric model for the ratio of the density
functions of survival times without considering a specific parametric model for each density
function. The non-mixture cure rate model that we discussed is an alternative to mixture
cure rate model, and provides a nice and more meaningful biological interpretation, especially
for cancer dataset.
7.2 Summary of simulation results and future work
The results of simulation studies in Chapter 4 show that all the models have smaller standard
error for estimation of parameters when sample size gets larger. This result implies consis-
tency of parameter estimates in each model. The application of proposed models on bone
marrow transplant dataset in Chapter 6 does not show significant estimates for parameters
except for the semi-parametric mixture cure model of Section 4.2.2 designed for dataset with
two groups of patients. This is mostly due to the fact that the dataset is relatively small. As
future work, if larger datasets are available, they could be used to validate the findings for
each model and perform appropriate comparisons of the results.
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APPENDIX A R IMPLEMENTATION OF MIXTURE QUANTILE
REGRESSION.
# computing H_gamma(u|W)
H_gam<-function(dat, u, gam){
n=nrow(dat)
gamW=apply(matrix(rep(gam,n),nrow=n,byrow=T)*dat[,colW],1,sum)
out=-log(1-logitf(gamW)*u)
return(out)
}
# computing the intergral
int_0<-function(dat, gam){
out=H_gam(dat,grd[1],gam)
return(out)
}
# computing the intergral
int_j<-function(dat, j, gam, betQS){
n=nrow(dat)
sum_j_0=rep(0,n)
sum_j_1=sum_j_0
tldZ=cbind(dat[,ncol(dat)],dat[,colZ])
for(k in (1:j)-1){
if(k==0){
sum_j_0=H_gam(dat,grd[1],gam)}
if(k!=0){
betQ=betQS[k,]
betQZ=exp(apply(matrix(rep(betQ,n),nrow=n,byrow=T)*tldZ,1,sum))
sum_j_1=sum_j_1+(dat[,1]>=betQZ)*(H_gam(dat,grd[k+1],gam) -
H_gam(dat,grd[k],gam))
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}
}
sum_j=sum_j_0+sum_j_1
out=tldZ*matrix(rep(sum_j,p1+1),nrow=n,byrow=F)
return(2*out)
}
# computing l_j(h)
l_j<-function(h,dat,j,gam,betQS){
n=nrow(dat)
bf_h=matrix(rep(h,n),nrow=n,byrow=T)
tldZ=cbind(dat[,ncol(dat)],dat[,colZ])
DltZ=tldZ*matrix(rep(dat[,2],p1+1),nrow=n,byrow=F)
bf_hDltZ=apply(bf_h*DltZ,1,sum)
term1=sum(abs(log(dat[,1])*dat[,2]-bf_hDltZ))
term2=abs(R_star+sum(bf_hDltZ))
term3=abs(R_star-sum(bf_h*int_j(dat, j, gam, betQS)))
out=term1+term2+term3
return(out)
}
# use L_1fit to find minimum value of l_j(h)
# computing response and covariate in l_j(h)
lad<-function(dat,j,gam,betQS){
n=nrow(dat)
tldZ=cbind(dat[,ncol(dat)],dat[,colZ])
DltZ=tldZ*matrix(rep(dat[,2],p1+1),nrow=n,byrow=F)
sumDltZ=-apply(DltZ,2,sum)
tmp1=int_j(dat, j, gam, betQS)
sumQuan=apply(tmp1,2,sum)
Y_resp=c(log(dat[,1])*dat[,2],R_star,R_star)
X_cov=rbind(DltZ,sumDltZ,sumQuan)
fitrq<-rq.fit(X_cov,Y_resp, tau=0.5, method="br", interp=FALSE)
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tmp2=fitrq$coeff
return(tmp2)
}
# replaceNA converts vector A to a matrix with first row equal to A and the
# rest of rows equal to NA.
replaceNA<-function(A){
for(j in 1:ncol(A)){
idx_nan=(is.nan(A[,j]) | is.na(A[,j]))*(1:nrow(A))
if(sum(idx_nan)>0){
idx1=idx_nan[idx_nan!=0]
A[idx1,j]=rep(A[min(idx1)-1,j],length(idx1))
}
}
return(A)
}
# use L_1fit to find minimum value of l_j(h)
l1fit_bet<-function(dat,gam,betQS){
n=nrow(dat)
for(jj in 1:lgrd){
betQS=replaceNA(betQS)
betQS[jj,]=lad(dat,jj,gam,betQS)
}
return(betQS)
}
# Sn_gam_rev1 function is a function that demonstrates equation S_n.
Sn_gam_rev1<-function(dat, j, gam, betQS){
n=nrow(dat)
gamW=apply(matrix(rep(gam,n),nrow=n,byrow=T)*dat[,colW],1,sum)
pigamW=logitf(gamW)
dpigamW=pigamW*(1-pigamW)
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tmpa_0=tmpa_1=tmpb_0=tmpb_1=rep(0,n)
dtmpa_0=dtmpa_1=dtmpb_0=dtmpb_1=rep(0,n)
tldZ=cbind(dat[,ncol(dat)],dat[,colZ])
for(k in 0:(j-1)){
if(k==0){
betQ_0=betQS[1,]
betQZ_1=exp(apply(matrix(rep(betQ_0,n),nrow=n,byrow=T)*tldZ,1,sum))
C0_1=1-pigamW
aa_0=grd[1]/2
C0_2=1-pigamW*aa_0
C0_3=dat[,2]*(dat[,1]<betQZ_1)
C0_4a=1-pigamW*grd[1]
C0_4b=1-pigamW*0
tmpa_0=C0_1*(C0_2^-1)*C0_3
tmpb_0=C0_1*(C0_4a^-1-(C0_4b^-1))
dC0_1=-dpigamW
dC0_2=-dpigamW*aa_0
dC0_4a=-dpigamW*grd[1]
dtmpa_0=(dC0_1*C0_2-C0_1*dC0_2)*(C0_2^-2)*C0_3
dtmpb_0=dC0_1*(C0_4a^-1-(C0_4b^-1))-C0_1*dC0_4a*(C0_4a^-2)
}
if(k!=0){
betQ_k=betQS[k,]
betQZ_k=exp(apply(matrix(rep(betQ_k,n),nrow=n,byrow=T)*tldZ,1,sum))
betQ_k1=betQS[k+1,]
betQZ_k1=exp(apply(matrix(rep(betQ_k1,n),nrow=n,byrow=T)*tldZ,1,sum))
C1_1=1-pigamW
aa_k=grd[k]/2+grd[k+1]/2
C1_2=1-pigamW*aa_k
C1_3=dat[,2]*(dat[,1]>=betQZ_k)*(dat[,1]<betQZ_k1)
C1_4a=1-pigamW*grd[k+1]
C1_4b=1-pigamW*grd[k]
C1_5=(dat[,1]>=betQZ_k)*1
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a_1=C1_1*(C1_2^-1)*C1_3
b_1=C1_1*((C1_4a^-1)-(C1_4b^-1))*C1_5
tmpa_1=tmpa_1+a_1
tmpb_1=tmpb_1+b_1
dC1_1=-dpigamW
dC1_2=-dpigamW*aa_k
dC1_4a=-dpigamW*grd[k+1]
dC1_4b=-dpigamW*grd[k]
da_1=(dC1_1*C1_2-C1_1*dC1_2)*(C1_2^-2)*C1_3
db_1=((dC1_1*C1_4a-C1_1*dC1_4a)*(C1_4a^-2)-
(dC1_1*C1_4b-C1_1*dC1_4b)*(C1_4b^-2))*C1_5
dtmpa_1=dtmpa_1+da_1
dtmpb_1=dtmpb_1+db_1
}
}
tmp=tmpa_0+tmpa_1-(tmpb_0+tmpb_1)
dtmp=dtmpa_0+dtmpa_1-(dtmpb_0+dtmpb_1)
Mtmp_W=dat[,colW]*matrix(rep(tmp,p2),nrow=n,byrow=F)
Mdtmp_W=dat[,colW]*matrix(rep(dtmp,p2),nrow=n,byrow=F)
out=apply(Mtmp_W,2,sum)
dout=t(dat[,colW])%*%Mdtmp_W
sdgam=matrix(1,ncol=p2,nrow=p2)
ans=list(out=out,dout=dout,sdgam=sdgam)
return(ans)
}
# NREEgam is a function that find gamma for rest of computations.
NREEgam<-function(dat,gam,betQS){
flag=1
ans=optim(gam,Sn_gam_nleqslv,
method="L-BFGS-B",lower=c( -20,-20,-20), upper = c( 20, 20,20))
gams=ans$par
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return(list(gam=gams,flag=flag))
}
# The final results for gamma and Beta, is obtained with following function.
iter2<-function(num,eps,dat,gam,betQS){
n=nrow(dat)
for(it in 1:num){
Flag0=Flag1=Flag2=Flag3=0
COND0=(sum(is.nan(betQS)) || sum(is.na(betQS)))
if(COND0){return(list(Flag0=Flag0,Flag1=Flag1,Flag2=Flag2))}
Flag0=1
ans1=l1fit_bet(dat,gam,betQS)
COND1=(sum(is.nan(ans1)) || sum(is.na(ans1)))
if(COND1){return(list(Flag0=Flag0,Flag1=Flag1,Flag2=Flag2))}
Flag1=1
ans_gam=NREEgam(dat,gam,ans1)
COND2=((!ans_gam$flag) || sum(is.nan(ans_gam$gam)))
if(COND2){return(list(Flag0=Flag0,Flag1=Flag1,Flag2=Flag2))}
Flag2=1
ans2=ans_gam$gam
if((max(abs(ans1-betQS))<=eps) && (max(abs(ans2-gam))<=eps)){
Flag3=1
return(list(Ebet=ans1,Egam=ans2,it=it,Flag0=Flag0,Flag1=Flag1,
Flag2=Flag2,Flag3=Flag3))
}
betQS<<-ans1
gam<<-ans2
}
return(list(Ebet=ans1,Egam=ans2,it=it,Flag0=Flag0,Flag1=Flag1,
Flag2=Flag2,Flag3=Flag3))
}
# link function to get cure probability for each individual.
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logitf<-function(gamW)
{
out<-exp(gamW)/(1+exp(gamW))
return(out)
}
# Function that has been used in NREEgam to be optimized.
Sn_gam_nleqslv<-function(x){
g<-c(x[1],x[2],x[3])
r<-Sn_gam_rev1(dat, j=lgrd, g, betQS)$out
out<-r[1]^2+r[2]^2+r[3]^2
return(out)
}
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APPENDIX B R IMPLEMENTATION OF TWO GROUPS MIXTURE
MODEL.
# p_i and q_i estimation
prob.estimate<-function(opt,psi,pla.event,tam.event,h)
{
hat_p<-c()
hat_q<-c()
a<-pla.event
b<-tam.event
ro<-length(b)/length(a)
hat_p<-(1/length(a))*(1/(1+ro*exp(opt$par[1]+
opt$par[2]*h+psi)))
hat_q<-exp(opt$par[1]+opt$par[2]*h+psi)*hat_p
return(list(Hp=hat_p,Hq=hat_q))
}
#parameter estimation
estimate<-function(h,tam.event,pla.event,ppsi=0,initial=c(0,0))
{
a<-tam.event
b<-pla.event
ro<-length(a)/length(b)
# Computing score function for Alpha.
f<-function(x)
{
length(a)-sum(1/
(1+(1/ro*exp(x[1]+x[2]*h))))
}
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# Computing score function for Beta.
g<-function(x)
{
sum(h[(length(a)+1):(length(b)+length(a))])-
sum(h/(1+1/(ro*exp(x[1]+x[2]*h))))
}
fg<-function(x)
{
f(x)^2+g(x)^2
}
myf<-fg(initial)
opt<-optim(par=initial,fn=fg,hessian=FALSE,method="Nelder-Mead")
return(list(opt=opt,myf.initial=myf))
}
# Function Psi.
ppsi<-function(X0,delta0,X1,delta1,y)
{
#\hat{H_0}
surv.obj.cen<-Surv(time=X0,event=(1-delta0))
kaplan.cen<-survfit(surv.obj.cen~1)
a.cen<-summary(kaplan.cen)
step.a.cen<-stepfun(x=a.cen$time,y=c(a.cen$surv[1],a.cen$surv))
#\hat{H_1}
surv.obj.tcen<-Surv(time=X1,event=(1-delta1))
kaplan.tcen<-survfit(surv.obj.tcen~1)
b.cen<-summary(kaplan.tcen)
step.b.cen<-stepfun(x=b.cen$time,y=c(b.cen$surv[1],b.cen$surv))
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# estimator for psi
ppsi<-c()
for(i in 1:length(y))
{
ppsi[i]<-log(step.b.cen(y[i])+0.0001)-log(step.a.cen(y[i])+0.0001)
}
return(ppsi)
}
# survival object for two groups of patients
surv.obj<-function(X0,delta0,X1,delta1)
{
surv.obj.pla<-Surv(time=X0,event=delta0)
kaplan.pla<-survfit(surv.obj.pla~1)
surv.obj.tam<-Surv(time=X1,event=delta1)
kaplan.tam<-survfit(surv.obj.tam~1)
y<-c(summary(kaplan.pla)$time,summary(kaplan.tam)$time)
return(list(su.pla=surv.obj.pla,ka.pla=kaplan.pla,su.tam=surv.obj.tam,
ka.tam=kaplan.tam,failur.times=y))
}
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APPENDIX C R IMPLEMENTATION OF NON-MIXTURE MODEL.
# simulation parameters:
# n, is number of individuals.
# p, is number of covariates.
# t.follow, is follow up time.
# a, is shape parameter.
# l, is scale parameter.
# X, is covariate matrix.
# tb, is the true coefficient functions.
# d, is the censoring indicator and probability of censoring is 0.06.
# t.theta, is true theta which has the formula theta=exp((x)^T B).
# P, is the cure rate which is different for each individual.
X<-scale(matrix(rnorm(p*n,mean=1),ncol=p))
t.theta=exp(X%*%tb)
d<-rbinom(n,size=1,prob=0.3)
P<-exp(-t.theta)
U<-runif(n,0,1)
quant<--log(U)/t.theta
tt<-qweibull(quant[-which(U<=P)], shape=a, scale=exp(-l))
t<-rep(NA,n)
t[which(U<=P)]<-t.follow
d[which(U<=P)]<-0
t[-which(U<=P)]<-tt
si<-pweibull(t,shape=a,scale=exp(l),lower.tail=FALSE)
N<-rpois(n,lambda=si*t.theta)+d
# Related functions.
# Computing Beta posterior function.
post.beta<-function(b,y,X,alpha,lambda,d)
{
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e<-10^-300
sh<-exp(-alpha)
si<-pweibull(y,shape=sh,scale=exp(-lambda),lower.tail=FALSE)+e
Xb<- X%*%b
loglike<-d*Xb-exp(Xb)*(1-si)
return(sum(loglike))
}
post.beta.mcmc1<-function(myb1)
{
return(post.beta(c(myb1,bb[2],bb[3]),t,X,alpha,lambda,d))
}
post.beta.mcmc2<-function(myb2)
{
return(post.beta(c(bb[1],myb2,bb[3]),t,X,alpha,lambda,d))
}
post.beta.mcmc3<-function(myb3)
{
return(post.beta(c(bb[1],bb[2],myb3),t,X,alpha,lambda,d))
}
# Computing psi=(alpha,lambda) posterior.
post.psi<-function(alpha,lambda,N,b,t,X,d)
{
e<-10^-300
sh<-exp(-alpha)
si<-pweibull(t,shape=sh,scale=exp(-lambda),lower.tail=FALSE)+e
fi<-dweibull(t,shape=sh,scale=exp(-lambda))+e
loglike<-(N-d)*log(si)+d*log(fi)
return(sum(loglike))
}
post.psi.mcmc1<-function(psi1)
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{
return(post.psi(alpha=psi1,lambda=lambda,N,bb,t,X,d))
}
post.psi.mcmc2<-function(psi2)
{
return(post.psi(alpha=alpha,lambda=psi2,N,bb,t,X,d))
}
prod.N<-function(X,t,tb,a,l,d)
{
t.theta=exp(X%*%tb)
si<-pweibull(t,shape=0.5,scale=1,lower.tail=FALSE)
N<-rpois(length(t),lambda=si*t.theta)+d
return(N)
}
# Computing gibb’s sampling.
gibbs<-function(tb,a=1,l=-1.5,Lim1,Lim2,data)
{
X<-data[,c("1","z1","w1")]
d<-data[,"d"]
t<-data[,"X"]
assign("X",X,envir = .GlobalEnv)
assign("d",d,envir = .GlobalEnv)
assign("t",t,envir = .GlobalEnv)
v.alpha<-c()
v.lambda<-c()
v.alpha[1]<-rgamma(1,shape=1,rate=1)
v.lambda[1]<-rnorm(1,sd=1)
beta<-matrix(ncol=length(tb),nrow=1)
beta[1,]<-tb
alpha<<-v.alpha[1]
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lambda<<-v.lambda[1]
bb<<-beta[1,]
N<<-prod.N(X,t,tb,a,l,d)
for(i in 1:Lim2)
{
out_beta1<-metrop(post.beta.mcmc1,initial=bb[1],1,scale=1)
bb[1]<<-out_beta1$batch
out_beta2<-metrop(post.beta.mcmc2,initial=bb[2],1,scale=1)
bb[2]<<-out_beta2$batch
out_beta3<-metrop(post.beta.mcmc3,initial=bb[3],1,scale=1)
bb[3]<<-out_beta3$batch
out_beta<-c(out_beta1$batch,out_beta2$batch,out_beta3$batch)
beta<-rbind(beta,out_beta)
out_psi1<-metrop(post.psi.mcmc1,initial=alpha,1,scale=1)
v.alpha[i+1]<-out_psi1$batch
assign("alpha",as.numeric(v.alpha[i+1]),envir = .GlobalEnv)
out_psi2<-metrop(post.psi.mcmc2,initial=lambda,1,scale=1)
v.lambda[i+1]<-out_psi2$batch
assign("lambda",as.numeric(v.lambda[i+1]),envir = .GlobalEnv)
}
mB0<-round(mean(beta[Lim1:Lim2,1]),digits=2)
mB1<-round(mean(beta[Lim1:Lim2,2]),digits=2)
mB2<-round(mean(beta[Lim1:Lim2,3]),digits=2)
mlam<-round(mean(v.lambda[Lim1:Lim2]),digits=2)
malp<-round(mean(v.alpha[Lim1:Lim2]),digits=2)
return(list(Alpha=malp,Lambda=mlam,Beta=c(mB0,mB1,mB2)
,V.beta=beta,V.lambda=v.lambda,V.alpha=v.alpha))
}
# Running the non-mixture model and Running bootstrap for estimating
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# parameter variance and p-value.
result<-function(Data=data,Iter,lim1=5,lim2=10,bootnum=200,B0=c(0,0,0))
{
n<-nrow(Data$dat)
mB0<-c()
mB1<-c()
mB2<-c()
mlam<-c()
malp<-c()
mydata<-Data$dat
res<-gibbs(tb=B0,a=1,l=-1.5,Lim1=lim1,Lim2=lim2,data=mydata)
bootresult<-vector(mod="list")
for(k in 1:bootnum)
{
newsample<-sample(n,replace=TRUE)
dat<-mydata[newsample,]
assign("dat",dat,envir = .GlobalEnv)
myit<-gibbs(tb=c(0,0,0),a=1,l=-1.5,Lim1=lim1,Lim2=lim2,data=dat)
bootresult[[k]]<-myit
}
Ebeta<-c()
Ealpha<-c()
Elambda<-c()
mbB<-c()
vbB<-c()
P_valB<-c()
ConfIntB<-c()
for(k in 1:bootnum)
{
b<-bootresult[[k]]$Beta
Ebeta<-rbind(b,Ebeta)
Ealpha[k]<-bootresult[[k]]$Alpha
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Elambda[k]<-bootresult[[k]]$Lambda
}
mbB<-apply(Ebeta,2,mean)
vbB<-apply(Ebeta,2,var)
matrix1<-abs(Ebeta - matrix(rep(mbB,each=bootnum),nrow=bootnum) )>
abs( res$Beta)
P_valB <-apply(matrix1,2,mean)
ConfIntB <- apply(Ebeta,2,function(x) quantile(x, c(.025, 0.975)))
mbAlpha<-mean(Ealpha)
vbAlpha<-var(Ealpha)
matrix2<-abs(Ealpha - rep(mbAlpha,times=bootnum) )> abs( res$Alpha)
P_valAlpha <-mean(matrix2)
ConfIntAlpha <- quantile(Ealpha, c(.025, 0.975))
mbLambda<-mean(Elambda)
vbLambda<-var(Elambda)
matrix3<-abs(Elambda - rep(mbLambda,times=bootnum) )> abs( res$Lambda)
P_valLambda <-mean(matrix3)
ConfIntLambda <- quantile(Elambda, c(.025, 0.975))
return(list(result0=res,Bootresult=bootresult,
BBeta=list(mean=mbB,var=vbB,P=P_valB,conf=ConfIntB),
BAlpha=list(mean=mbAlpha,var=vbAlpha,P=P_valAlpha,conf=ConfIntAlpha),
BLambda=list(mean=mbLambda,var=vbLambda,P=P_valLambda,conf=
ConfIntLambda)))
}
